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A B S T R A C T
Background
Tinnitus affects 10% to 15% of the adult population, with about 20% of these experiencing symptoms that negatively affect quality of
life. In England alone there are an estimated ¾ million general practice consultations every year where the primary complaint is tinnitus,
equating to a major burden on healthcare services. Clinical management strategies include education and advice, relaxation therapy,
tinnitus retraining therapy (TRT), cognitive behavioural therapy (CBT), sound enrichment using ear-level sound generators or hearing
aids, and drug therapies to manage co-morbid symptoms such as insomnia, anxiety or depression. Hearing aids, sound generators
and combination devices (amplification and sound generation within one device) are a component of many tinnitus management
programmes and together with information and advice are a first line of management in audiology departments for someone who has
tinnitus.
Objectives
To assess the effects of sound therapy (using amplification devices and/or sound generators) for tinnitus in adults.
Search methods
The Cochrane ENT Information Specialist searched the Cochrane ENT Register; Central Register of Controlled Trials (CENTRAL,
via the Cochrane Register of Studies); Ovid MEDLINE; Ovid Embase; CINAHL; Web of Science; ClinicalTrials.gov; ICTRP and
additional sources for published and unpublished trials. The date of the search was 23 July 2018.
Selection criteria
Randomised controlled trials (RCTs) recruiting adults with acute or chronic subjective idiopathic tinnitus. We included studies where
the intervention involved hearing aids, sound generators or combination hearing aids and compared them to waiting list control, placebo
or education/information only with no device. We also included studies comparing hearing aids to sound generators, combination
hearing aids to hearing aids, and combination hearing aids to sound generators.
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Data collection and analysis
We used the standard methodological procedures expected by Cochrane. Our primary outcomes were tinnitus symptom severity as
measured as a global score on multi-item tinnitus questionnaire and significant adverse effects as indicated by an increase in self-reported
tinnitus loudness. Our secondary outcomes were depressive symptoms, symptoms of generalised anxiety, health-related quality of life
and adverse effects associated with wearing the device such as pain, discomfort, tenderness or skin irritation, or ear infections. We used
GRADE to assess the quality of evidence for each outcome; this is indicated in italics.
Main results
This review included eight studies (with a total of 590 participants). Seven studies investigated the effects of hearing aids, four
combination hearing aids and three sound generators. Seven studies were parallel-group RCTs and one had a cross-over design. In
general, risk of bias was unclear due to lack of detail about sequence generation and allocation concealment. There was also little or no
use of blinding.
No data for our outcomes were available for any of our three main comparisons (comparing hearing aids, sound generators and
combination devices with a waiting list control group, placebo or education/information only). Data for our additional comparisons
(comparing these devices with each other) were also few, with limited potential for data pooling.
Hearing aid only versus sound generator device only
One study compared patients fitted with sound generators versus those fitted with hearing aids and found no difference between them
in their effects on our primary outcome, tinnitus symptom severity measured with the Tinnitus Handicap Inventory (THI) at 3, 6
or 12 months (low-quality evidence). The use of both types of device was associated with a clinically significant reduction in tinnitus
symptom severity.
Combination hearing aid versus hearing aid only
Three studies compared combination hearing aids with hearing aids and measured tinnitus symptom severity using the THI or Tinnitus
Functional Index. When we pooled the data we found no difference between them (standardised mean difference -0.15, 95% confidence
interval -0.52 to 0.22; three studies; 114 participants) (low-quality evidence). The use of both types of device was again associated with
a clinically significant reduction in tinnitus symptom severity.
Adverse effects were not assessed in any of the included studies.
None of the studies measured the secondary outcomes of depressive symptoms or depression, anxiety symptoms or generalised anxiety,
or health-related quality of life as measured by a validated instrument, nor the newly developed core outcomes tinnitus intrusiveness,
ability to ignore, concentration, quality of sleep and sense of control.
Authors’ conclusions
There is no evidence to support the superiority of sound therapy for tinnitus over waiting list control, placebo or education/information
with no device. There is insufficient evidence to support the superiority or inferiority of any of the sound therapy options (hearing
aid, sound generator or combination hearing aid) over each other. The quality of evidence for the reported outcomes, assessed using
GRADE, was low. Using a combination device, hearing aid or sound generator might result in little or no difference in tinnitus symptom
severity.
Future research into the effectiveness of sound therapy in patients with tinnitus should use rigorous methodology. Randomisation and
blinding should be of the highest quality, given the subjective nature of tinnitus and the strong likelihood of a placebo response. The
CONSORT statement should be used in the design and reporting of future studies. We also recommend the use of validated, patient-
centred outcome measures for research in the field of tinnitus.
P L A I N L A N G U A G E S U M M A R Y
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Review question
Is sound therapy (using amplification devices, sound generators or both) effective for tinnitus in adults?
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Background
Tinnitus is the awareness of a sound in the ear or head without any outside source. It affects 10% to 15% of the adult population. About
20% of people with tinnitus experience symptoms that negatively affect their quality of life including sleep disturbances, difficulties
with hearing and concentration, social isolation, anxiety, depression, irritation or stress. Tinnitus can be managed through education
and advice, relaxation therapy, psychological therapy, or devices that improve hearing or generate sound such as sound generators or
hearing aids. Sometimes drugs are prescribed to manage problems associated with tinnitus such as sleep problems, anxiety or depression.
The purpose of this review is to evaluate the evidence from high-quality clinical trials to work out the effects of sound therapy (hearing
aids, sound generators and combination hearing aids) on adults with tinnitus. We particularly wanted to look at the effects of sound
therapy on tinnitus severity and any side effects.
Study characteristics
Our review identified eight randomised controlled trials with 590 participants in total. Seven studies looked at the effects of hearing
aids, four combination hearing aids and three sound generators. Seven studies allocated participants into parallel groups and in one
study participants tried each intervention in a random order. The outcomes that we looked for were severity of tinnitus symptoms,
depression, anxiety, quality of life and side effects. In general, the risk of bias in the studies was unclear. There was also little or no use
of blinding.
Key results
We did not find any data for our outcomes for any of our three main comparisons (comparing hearing aids, sound generators and
combination devices with a waiting list control group, placebo or education/information only). There were also few data for our
additional comparisons (comparing these devices with each other) and it was difficult to pool (combine) the data.
Hearing aid only versus sound generator device only
One study compared patients fitted with sound generators with those fitted with hearing aids and found no difference between them in
their effects on our primary outcome, tinnitus symptom severity, at 3, 6 or 12 months. The use of both types of device was associated
with a clinically significant reduction in tinnitus symptom severity.
Combination hearing aid versus hearing aid only
Three studies compared combination hearing aids/sound generators with hearing aids alone and measured tinnitus symptom severity.
When we combined the data for tinnitus symptom severity we found no difference between them. The use of both types of device was
again associated with a clinically significant reduction in tinnitus symptom severity.
Adverse effects were not assessed in any of the included studies.
None of the studies measured depressive symptoms or depression, anxiety symptoms or generalised anxiety, or other important outcomes
of interest in this review.
Quality of evidence
Where outcomes that we were interested in for this review were reported, we assessed the quality of the evidence available as low. Using
a hearing aid, sound generator or combination device might result in little or no difference in tinnitus symptom severity.
3Sound therapy (using amplification devices and/or sound generators) for tinnitus (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Hearing aid compared to sound generator for tinnitus in adults
Patient or population: adults with t innitus
Setting: audiology
Intervention: amplif icat ion only
Comparison: sound generator













Scale f rom: 0 to 100
Follow-up: mean 3
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The mean score for t in-
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was -18.9 points
The mean score for t in-
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ciated with wearing the
device (such as pain,
discomfort , tenderness
or skin irritat ion, or ear
infect ions)
Not measured
CI: conf idence interval
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Serious risk of bias due to lack of blinding of part icipants and personnel, unclear risk of bias for allocat ion concealment,
blinding of outcome assessments and attrit ion bias.













































































































B A C K G R O U N D
This new review supersedes two earlier Cochrane Reviews on
sound therapy (masking) and on amplification with hearing aids
for tinnitus that were first published in the Cochrane Library in
Issue 12, 2010 and updated in 2012 (Hobson 2012) and in Is-
sue 1, 2014 (Hoare 2014), respectively. The following paragraphs
and Description of the condition are based on the latter Cochrane
Review ’Amplification with hearing aids for patients with tinnitus
and co-existing hearing loss’ and are reproduced with permission
(Hoare 2014).
Tinnitus is defined as the perception of sound in the absence of
an external source (Jastreboff 2004). It is typically described by
those who experience it as a ringing, hissing, buzzing or whoosh-
ing sound and is thought to result from abnormal neural activity
at some point or points in the auditory pathway, which is erro-
neously interpreted by the brain as sound. Tinnitus can be either
objective or subjective. Objective tinnitus refers to the perception
of sound that can be also heard by the examiner and is usually due
to turbulent blood flow or muscular contraction (Roberts 2010).
Most commonly, however, tinnitus is subjective; the sound is only
heard by the person experiencing it and no source of the sound is
identified (Jastreboff 1988).
Tinnitus affects between 5% and 43% of the general population
and prevalence increases with age (McCormack 2016). It can be
experienced acutely, recovering spontaneously within minutes to
weeks, but is considered chronic and unlikely to resolve sponta-
neously when experienced for more than three months (Gallus
2015; Hall 2011).
For many people tinnitus is persistent and troublesome, and has
disabling effects such as insomnia, difficulty concentrating, dif-
ficulties in communication and social interaction, and negative
emotional responses such as anxiety and depression (Hall 2018).
In approximately 90% of cases, chronic tinnitus is co-morbid with
some degree of measurable hearing loss, which may confound
these disabling effects (Fowler 1944; Sanchez 2002). Nevertheless,
the association between hearing loss and tinnitus is not simple or
straightforward; not all people with hearing loss experience tin-
nitus, and conversely some people with clinically normal hearing
have tinnitus (Baguley 2013). It has been reported that 40% of
patients are unable to identify what health condition is associated
with their tinnitus onset, i.e. the tinnitus is idiopathic (Henry
2005).
An important implication in clinical research is that outcome mea-
sures need to distinguish benefits specific to improved hearing
from those specific to improvement in the psychological aspects
of tinnitus.
Description of the condition
Diagnosis and clinical management of tinnitus
There is no standard procedure for the diagnosis or management of
tinnitus. Practice guidelines and the approaches described in stud-
ies of usual clinical practice typically reflect differences between
the clinical specialisms of the authors or differences in the clinical
specialisms charged with meeting tinnitus patients’ needs (medi-
cal, audiology/hearing therapy, clinical psychology, psychiatry), or
the available resources of a particular country or region (access to
clinicians or devices, for example) (Biesinger 2010; Cima 2012;
Department of Health 2009; Hall 2011; Henry 2008; Hoare
2011). Common across all these documents, however, is the use or
recommendation of written questionnaires to assess tinnitus and
its impact on patients and their families by measuring tinnitus
symptom severity (e.g. impact of tinnitus on quality of life, activ-
ities of daily living or sleep), and a judgement about patients who
are experiencing a degree of psychological distress (depression or
anxiety). Assessment of the perceptual characteristics of tinnitus
(pitch, loudness, minimum masking level) and residual inhibition
are also recommended (Cima 2018). Although these measures do
not correlate well with tinnitus symptom severity (Hiller 2006),
they can prove useful in patient counselling (Henry 2004), as a
baseline before start of treatment (El Refaie 2004), or by demon-
strating stability of the tinnitus percept over time (Department of
Health 2009).
Clinical management strategies include education and advice, re-
laxation therapy, tinnitus retraining therapy (TRT), cognitive be-
havioural therapy (CBT), sound enrichment using ear-level sound
generators or hearing aids, and drug therapies to manage co-mor-
bid symptoms such as insomnia, anxiety or depression (for exam-
ple, Department of Health 2009; Tunkel 2014). As yet, no drug
has been approved for tinnitus by a regulatory body (e.g. the Eu-
ropean Medicines Agency or US Food and Drug Administration).
Pathophysiology
Most people with chronic tinnitus have some degree of measur-
able hearing loss (Ratnayake 2009), and the prevalence of tinnitus
increases with greater hearing loss (Han 2009; Martines 2010).
The varying theories of tinnitus generation involve changes in ei-
ther function or activity of the peripheral (cochlea and auditory
nerve) or central auditory nervous systems (Henry 2005). Theo-
ries involving the peripheral systems include the discordant dam-
age theory, which predicts that the loss of outer hair cell function,
where inner hair cell function is left intact, leads to a release from
inhibition of inner hair cells and aberrant activity (typically hy-
peractivity) in the auditory nerve (Jastreboff 1990). Such aberrant
auditory nerve activity can also have a biochemical basis, resulting
from excitotoxicity or stress-induced enhancement of inner hair
cell glutamate release with upregulation of N-methyl-D-aspartate
(NMDA) receptors (Guitton 2003; Sahley 2001).
In the central auditory system, structures implicated as possible
sites of tinnitus generation include the dorsal cochlear nucleus
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(Middleton 2011; Pilati 2012), the inferior colliculus (Dong 2010;
Mulders 2010), and the auditory and non-auditory cortex (dis-
cussed further below). There is a strong rationale that tinnitus is a
direct consequence of maladaptive neuroplastic responses to hear-
ing loss (Moller 2000; Muhlnickel 1998). This process is triggered
by sensory deafferentation and a release from lateral inhibition in
the central auditory system allowing irregular spontaneous hyper-
activity within the central neuronal networks involved in sound
processing (Eggermont 2004; Rauschecker 1999; Seki 2003). As
a consequence of this hyperactivity, a further physiological change
noted in tinnitus patients is increased spontaneous synchronous
activity occurring at the subcortical and cortical level, measurable
using electroencephalography (EEG) or magnetoencephalography
(MEG) (Dietrich 2001; Tass 2012; Weisz 2005). Another physi-
ological change thought to be involved in tinnitus generation is a
process of functional reorganisation, which amounts to a change
in the response properties of neurons within the primary auditory
cortex to external sounds. This effect is well demonstrated physio-
logically in animal models of hearing loss (Engineer 2011; Norena
2005). Evidence in humans, however, is limited to behavioural
evidence of cortical reorganisation after hearing loss, demonstrat-
ing improved frequency discrimination ability at the audiomet-
ric edge (Kluk 2006; McDermott 1998; Moore 2009; Thai-Van
2002; Thai-Van 2003), although Buss 1998 did not find this ef-
fect. For comprehensive reviews of these physiological models, see
Adjamian 2009 and Norena 2011.
It is also proposed that spontaneous hyperactivity could cause an
increase in sensitivity or ’gain’ at the level of the cortex, whereby
neural sensitivity adapts to the reduced sensory inputs, in effect
stabilising mean firing and neural coding efficiency (Norena 2011;
Schaette 2006; Schaette 2011). Such adaptive changes would be
achieved at the cost of amplifying ’neural noise’ due to the overall
increase in sensitivity, ultimately resulting in the generation of
tinnitus.
Increasingly, non-auditory areas of the brain, particularly areas as-
sociated with emotional processing, are also implicated in bother-
some tinnitus (Rauschecker 2010; Vanneste 2012). Vanneste 2012
describes tinnitus as “an emergent property of multiple parallel
dynamically changing and partially overlapping sub-networks”,
implicating the involvement of many structures of the brain more
associated with memory and emotional processing in tinnitus gen-
eration. However, identification of the structural components of
individual neural networks responsible for either tinnitus gener-
ation or tinnitus intrusiveness, which are independent of those
for hearing loss, remains open to future research (Melcher 2013).
One further complication in understanding the pathophysiology
of tinnitus is that not all people with hearing loss have tinnitus
and not all people with tinnitus have a clinically significant and
measurable hearing loss. Other variables, such as the profile of a
person’s hearing loss, may account for differences in their tinnitus
report. For example, Konig 2006 found that the maximum slope
within audiograms was higher in people with tinnitus than in peo-
ple with hearing loss who do not have tinnitus, despite the ’non-
tinnitus’ group having the greater mean hearing loss. This sug-
gests that a contrast in sensory inputs between regions of normal
and elevated threshold may be more likely to result in tinnitus.
However, this finding is not consistent across the literature (Sereda
2011; Sereda 2015a).
Description of the intervention
Amplification devices (hearing aids)
The following description of hearing aids is taken from the
Cochrane Review ’Amplification with hearing aids for patients
with tinnitus and co-existing hearing loss’ and reproduced with
permission Hoare 2014.
The standard function of a hearing aid is to amplify and modulate
sound, primarily for the purpose of making sound more accessible
and aiding communication. Using hearing aids in tinnitus man-
agement has been proposed as a useful strategy since the 1940s
(Saltzman 1947), although benefit reportedly varies and there is no
clear consensus on when a person would or would not benefit from
amplification (Henry 2005; Hoare 2012). Beck 2011 proposes
that hearing aid fittings for people with very mild up to moderate
sensorineural hearing loss (who might not ordinarily look for or
be prescribed a hearing aid) can lead to significant improvements
in tinnitus. Currently, hearing aids, supplemented with education
and advice, form a common intervention for someone who has
tinnitus and an aidable hearing loss (Hoare 2012; Sereda 2015).
This combination of hearing aid provision with education and
advice might be considered a complex intervention with interde-
pendent components (Shepperd 2009).
There are many options for hearing aid fitting that complicate
their use in tinnitus. For example, Del Bo 2007 suggests that the
best clinical result for someone with tinnitus requires binaural am-
plification. Trotter 2008, however, in describing a 25-year expe-
rience of hearing aids in tinnitus therapy found no difference in
tinnitus improvement between unilaterally and bilaterally aided
patients.
For other aspects of hearing aid fitting there appears greater con-
sensus, such as the value of using open-fitting aids (if acoustically
suitable), which allow natural environmental sound to enter the
ear, as well as amplifying those sounds, thus improving perceived
sound quality (Del Bo 2007; Forti 2010).
The bandwidth amplified by the hearing aid may also be impor-
tant to its effect on tinnitus. In a study by Moffat 2009 the tinnitus
percept was not at all affected in a group receiving high-bandwidth
amplification, which had less gain at frequencies below 1 kHz and
more gain at frequencies above 1 kHz than conventional ampli-
fication. In a group receiving conventional amplification, how-
ever, there was a significant reduction of the contribution of all
low-frequency components of the measured tinnitus spectrum to
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matched tinnitus. This suggests an interaction between the per-
ceptual characteristics of tinnitus and the pattern of sensory inputs
in this group.
Finally, hearing aid prescription might also be combined with
other forms of therapy such as formal counselling, albeit with
mixed evidence for the efficacy of such combinations of therapies
(Hiller 2005; Searchfield 2010).
Sound generator devices
Sound generators are ear-level devices that produce sounds for
therapeutic use.
Sound generator devices were introduced in 1976, on the prin-
ciple of distraction, turning complete masking of tinnitus with
white noise into a clinical management technique (Vernon 1976).
The purpose of the ’masking’ method was described by Vernon
as making the tinnitus inaudible with a more acceptable sound
(Vernon 1976; Vernon 1977). With the introduction of combina-
tion hearing aids partial masking became an acceptable outcome
of the sound therapy. Partial masking provided only partial reduc-
tion in tinnitus, meaning that the tinnitus could still be heard but
in a suppressed form (Vernon 1988).
Current views on sound generators acknowledge that masking is
only one of the goals of sound therapy, alongside achieving tinnitus
relief (i.e. reduction in tinnitus annoyance) regardless of the mech-
anism by which it is achieved (complete masking, partial masking
or not masking the tinnitus; Henry 2008a). Other philosophies
include the use of noise as a form of sound enrichment, counter-
acting the effects of sensory deprivation (Jastreboff 1993).
Recommendations regarding choice of sounds or level of sound
that should be used vary across the literature and often strongly
depend on the management programme followed. For example,
tinnitus masking (TM) permits the use of any sound that provides
maximum masking benefit (Henry 2002). The choice of sound,
therefore, is based on a combination of effectiveness and accept-
ability for the patient. On the other hand, tinnitus retraining ther-
apy (TRT) recommends the use of broadband noise to be adjusted
to a ’mixing’ or ’blending’ point (Jastreboff 2007; Korres 2010;
McFerran 2009), or below that level (Jastreboff 2006), to allow
for habituation.
Many studies describe sound therapy in the context of a larger
management programme, combining multiple approaches to
manage tinnitus, where the counselling component plays a major
role (e.g. Progressive Tinnitus Management, TRT, Neuromonics).
It is therefore often difficult or even impossible to draw conclu-
sions specific to the sound therapy component of the programme.
It is possible that other components, rather than the devices, might
have played a role in the observed improvements in tinnitus dis-
tress or handicap.
Combination hearing aids
Combination hearing aids combine amplification and sound gen-
eration options within one device, and new generations of such
devices offer the same quality of amplification as ’standard’ hearing
aids (Henry 2004a; Sereda 2017; Tutaj 2018).
How the intervention might work
Hearing aids may be beneficial for people with tinnitus in a num-
ber of ways. The amplification of external sounds may reverse or
reduce the drive responsible for ’pathological’ changes in the cen-
tral auditory system associated with hearing loss, such as increased
gain or auditory cortex reorganisation, possibly by strengthen-
ing lateral inhibitory connections. Increased neuronal activity that
results from amplified sounds may reduce the contrast between
tinnitus activity and background activity thus reducing the audi-
bility and awareness of tinnitus. Alternatively, amplification may
simply refocus attention on alternative auditory stimuli that are
incompatible and unrelated to the tinnitus sound. As the main
function of hearing aids is to improve communication, for many
people this inherently reduces stress and anxiety (Carmen 2002;
Surr 1985), and so may indirectly affect improvements in tinnitus
report. Finally, it is unquestioned that there is the potential for a
large placebo effect in any study of tinnitus (Dobie 1999), and
so it is essential that any investigation of hearing aids for tinnitus
considers the potential impact of this effect.
Postulated mechanisms through which sound generators may be
beneficial for tinnitus include tinnitus masking by reducing au-
dibility (Vernon 1977) or by inducing a sense of relief (Vernon
2000), through habituation (Jastreboff 1993), by reversing abnor-
mal cortical reorganisation or activity thought to contribute to
tinnitus (Norena 2005; Tass 2012), or through the promotion of
relaxation (Sweetow 2010).
Combination hearing aids combine the above approaches within
one device (Tutaj 2018).
Potential modifiers of treatment outcome include the presence of
hearing loss, clinically significant anxiety or depression, or high
levels of tinnitus distress (which may be intractable to sound ther-
apy alone) (Hoare 2012; Hoare 2014a; Jastreboff 2004; Searchfield
2010; Searchfield 2017).
Why it is important to do this review
In England alone there are an estimated ¾ million general prac-
tice consultations every year where the primary complaint is tinni-
tus (El-Shunnar 2011), equating to a major burden on healthcare
services. Hearing aids, sound generators and combination devices
(amplification aid sound generation within one device) are a com-
ponent of many tinnitus management programmes and together
with information and advice are a first line of management in
UK audiology departments for someone who has tinnitus (Hoare
2014; Hobson 2012; Sereda 2015; Tutaj 2018). These options are
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also subject to ongoing research and development, for example to
examine the effectiveness of new technologies such as mobile ap-
plications, wireless streaming and alternative sound options such
as 3D sounds (Tutaj 2018).
Two previous Cochrane Reviews concluded that there was a
lack of evidence for the effectiveness of these management op-
tions (Hobson 2012; Hoare 2014). The first review looked at
sound therapy (masking) in the management of tinnitus in adults
(Hobson 2012). The methods and searches in that review are now
outdated, as is the use of term ’masking’ as the only suggested
mechanism of action for sound therapy. The second review looked
at amplification with hearing aids for patients with tinnitus and
co-existing hearing loss and an update of that review is now due
(Hoare 2014). The current review provides an update to both of
these Cochrane Reviews and extends them to separately consider
the specific effects and safety of the three different sound therapy
options.
O B J E C T I V E S
To assess the effects of sound therapy (using amplification devices
and/or sound generators) for tinnitus in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included studies with the following design characteristics:
• randomised controlled trials, including cluster-randomised
(cross-over trials were eligible if data from before the cross-over
could be extracted, to avoid the potential for a carry-over
phenomenon).
We excluded studies with the following design characteristics:
• quasi-randomised controlled studies.
We applied no restrictions on language, year of publication or
publication status.
Types of participants
Adults (≥ 18 years) with acute (≤ 3 months) or chronic (> 3
months) subjective idiopathic tinnitus.
Types of interventions
Amplification-only devices, sound generators and combination
devices (combined amplification and sound generation).
The comparators were amplification only, sound generator only
and combination device.
The main comparison pair(s) were:
• amplification only versus waiting list control or placebo or
education/information only with no device;
• sound generator only versus waiting list control or placebo
or education/information only with no device;
• combination device versus waiting list control or placebo or
education/information only with no device.
Other possible comparison pairs included:
• amplification only versus sound generator only;
• combination device versus amplification only;
• combination device versus sound generator only.
We excluded studies evaluating complex interventions, which ex-
plicitly included a sound therapy and other non-sound compo-
nents (e.g. psychotherapy) as a part of a programme (e.g. Neu-
romonics). We excluded studies of neuromodulation (desynchro-
nisation) devices (reviewed in Hoare 2015).
Types of outcome measures
We planned to analyse the following outcomes in the review, but
we did not use them as a basis for including or excluding studies.
Primary outcomes
• Tinnitus symptom severity (such as the impact of tinnitus
on quality of life, activities of daily living and sleep), as measured
by the global score on a multi-item tinnitus questionnaire (Table
1). These included:
◦ Tinnitus Questionnaire (Hallam 1996; Hiller 1992);
◦ Tinnitus Functional Index (TFI) (Meikle 2012);
◦ Tinnitus Handicap Inventory (THI) (Newman 1996);
◦ Tinnitus Handicap Questionnaire (Kuk 1990);
◦ Tinnitus Reaction Questionnaire (Wilson 1991);
◦ Tinnitus Severity Scale (Sweetow 1990).
• Significant adverse effect: increase in self-reported tinnitus
loudness.
Secondary outcomes
• Depressive symptoms or depression as measured by a
validated instrument, such as the Beck Depression Inventory
(Beck 1988; Beck 1996), the depression scale of the Hospital
Anxiety and Depression Scale (HADS; Zigmond 1983), and the
Hamilton Rating Scale for Depression (Hamilton 1960).
• Anxiety symptoms or generalised anxiety as measured by a
validated instrument, such as the anxiety scale of the Beck
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Anxiety Inventory (Beck 1988), the anxiety scale of the HADS
(Zigmond 1983), or the Anxiety Sensitivity Index (Reiss 1986).
• Health-related quality of life as measured by a validated
instrument, such as the Short-Form 36 (Hays 1993),
WHOQOLBREF (Skevington 2004), other WHOQOL
versions or Health Utilities Index (Furlong 2001).
• Adverse effects associated with wearing the device such as
pain, discomfort, tenderness or skin irritation, or ear infections.
In addition, we planned to report the newly developed core out-
comes for trials of sound therapy for tinnitus, these being tinnitus
intrusiveness, ability to ignore, concentration, quality of sleep
and sense of control (Hall 2018a).
We reported long-term effects as three to six months.
Search methods for identification of studies
The Cochrane ENT Information Specialist conducted systematic
searches for randomised controlled trials and controlled clinical
trials. There were no language, publication year or publication
status restrictions. The date of the search was 23 July 2018.
Electronic searches
The Information Specialist searched:
• the Cochrane ENT Register (searched via the Cochrane
Register of Studies 23 July 2018);
• the Cochrane Central Register of Controlled Trials
(CENTRAL) (searched via the Cochrane Register of Studies 23
July 2018);
• Ovid MEDLINE(R) Epub Ahead of Print, In-Process &
Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and
Ovid MEDLINE(R) (1946 to 23 July 2018);
• Ovid EMBASE (1974 to 23 July 2018);
• LILACS (Latin American and Caribbean Health Science
Information database), lilacs.bvsalud.org (searched 23 July
2018);
• Web of Knowledge, Web of Science (1945 to 23 July 2018);
• EBSCO CINAHL (1982 to 23 July 2018);
• Ovid PsycINFO (1910 to 23 July 2018);
• ClinicalTrials.gov, (searched via the Cochrane Register of
Studies 23 July 2018);
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP), www.who.int/ictrp (searched
23 July 2018).
The Information Specialist modelled subject strategies for
databases on the search strategy designed for CENTRAL. Where
appropriate, they were combined with subject strategy adaptations
of the highly sensitive search strategy designed by Cochrane for
identifying randomised controlled trials and controlled clinical tri-
als (as described in the Cochrane Handbook for Systematic Reviews of
Interventions Version 5.1.0, Box 6.4.b. (Handbook 2011). Search
strategies for major databases including CENTRAL are provided
in Appendix 1.
Searching other resources
We scanned the reference lists of identified publications for addi-
tional trials and contacted trial authors if necessary. In addition,
the Information Specialist searched Ovid MEDLINE to retrieve
existing systematic reviews relevant to this systematic review, so
that we could scan their reference lists for additional trials. The
Information Specialist also ran non-systematic searches of Google
Scholar to retrieve grey literature and other sources of potential
trials.
We did not perform a separate search for adverse effects of sound
therapy (using amplification devices and/or sound generators) for
tinnitus. We considered adverse effects described in the included
studies only.
Data collection and analysis
Selection of studies
Two out of three authors (MS, AER and DAH) independently
reviewed each study retrieved to determine their eligibility for
inclusion in the review. Four further authors (MS, DJH, AER,
and JX) then reviewed the full-text reports of the retrieved studies
and applied the inclusion criteria independently. We discussed any
disagreements until a consensus was reached.
Data extraction and management
MS, DJH, AER and JX independently extracted data using a pur-
posefully designed data extraction form. We piloted the data ex-
traction form on a subset of articles and revised it as indicated
before formal data extraction began. Where necessary or where
insufficient data were provided for the study, we contacted study
authors for further information.
Information extracted included: study design, setting, methods or
randomisation and blinding, power, inclusion and exclusion cri-
teria, type of intervention and control, treatment duration, treat-
ment fidelity, type and duration of follow-up, and outcome mea-
sures and statistical tests.
Data extracted included: baseline characteristics of participants
(age, sex, duration of tinnitus, tinnitus symptom severity, tinnitus
loudness and pitch estimates, details of co-morbid hearing loss,
anxiety or depression) and details of any attrition or exclusion.
Outcome data included: group mean and standard deviation at
pre- and post-intervention and follow-up, and results of any sta-
tistical tests of between-group comparisons.
Where not reported or provided by the authors we estimated stan-
dard deviations in RevMan 5.3 (RevMan 2014) using the available
data, such as standard errors, confidence intervals, P values and t
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values. Where data were only available in graph form, we made
and agreed numeric estimates.
After independent data extraction by MS, DJH, AER and JX, all
authors reviewed the extracted data for disagreements, and revis-
ited and discussed the relevant studies as required to reach a final
consensus.
Assessment of risk of bias in included studies
MS, DJH, AER and JX independently assessed risk of bias of the
included studies, with the following taken into consideration, as





• incomplete outcome data;
• selective outcome reporting; and
• other sources of bias.
We used the Cochrane ’Risk of bias’ tool in RevMan 5.3 (RevMan
2014), which involves describing each of these domains as reported
in the study and then assigning a judgement about the adequacy
of each entry: ’low’, ’high’ or ’unclear’ risk of bias. We resolved
differences of opinion by discussion.
Measures of treatment effect
We analysed dichotomous data as risk ratios (RR) with 95% con-
fidence intervals (CIs). We summarised continuous outcomes as
mean difference (MD) with 95% CI. We used the standardised
mean difference (SMD) (Cohen’s d effect size (ES)) when different
scales of measurement were used to measure the same outcome.
A positive effect size indicated that the treatment group achieved
better outcomes than the control group.
Unit of analysis issues
For parallel-group RCTs the unit of analysis was the group mean.
To avoid unit of analysis errors we planned to consider alterna-
tive analyses for cluster-randomised trials and for studies with
more than two intervention groups. For cluster-randomised tri-
als we planned to adopt approximate analyses - effective sample
sizes (Donner 2002). For studies with more than two intervention
groups, we planned either to combine groups to create a single
pair-wise comparison or, if this was not appropriate, to select the
most relevant pair of interventions for comparison.
Dealing with missing data
Where necessary and where sufficient data from the study were
not provided, we contacted authors of the study requesting further
details about missing data and reasons for the incompleteness of
the data. We were alert to potential mislabelling or non-identifi-
cation of standard errors and standard deviations. Our method for
imputation was according to chapter 7.7.3 of the Cochrane Hand-
book for Systematic Reviews of Interventions (Handbook 2011). If
data were missing, we used available case analysis using all data
(as reported) for all randomised patients available at the end of
the study/time point of interest, regardless of the actual treatment
received. We considered the quality of outcome assessment as a
study limitation (GRADE) and not as a stratifying factor.
Assessment of heterogeneity
We assessed studies for clinical, statistical and methodological het-
erogeneity. We quantified statistical heterogeneity using the I2
statistic and the Chi2 test. An approximate guide to interpretation
of the I2 statistic is provided in the Cochrane Handbook for System-
atic Reviews of Interventions (Handbook 2011). An I2 value of 50%
or higher may represent substantial or considerable heterogeneity.
Where Chi2 is greater than the degrees of freedom (K-1 degrees of
freedom, where K is the number of studies), then heterogeneity is
likely to be present. We considered heterogeneity to be statistically
significant if the P value was less than 0.10. We performed meta-
analysis using fixed-effect modelling.
Assessment of reporting biases
For each sound therapy intervention, we investigated potential
publication bias and the influence of individual studies on the
overall outcome identified in this review. We searched for and re-
quested study protocols for the included studies and, where avail-
able, we evaluated whether there was evidence of selective report-
ing. There were too few studies included to assess publication bias.
Data synthesis
We analysed separately the different sound therapy options (am-
plification only, sound generation only, combined amplification
and sound generation) and different durations of tinnitus (acute
and chronic). We performed only one meta-analysis comparing
combination hearing aids to amplification only.
We pooled data using a fixed-effect model and SMD.
We considered the psychometric properties of outcome instru-
ments with regard to their suitability for pooling. For meta-anal-
yses on the primary outcome (tinnitus symptom severity), when-
ever studies reported outcomes measured by more than one instru-
ment, we included data only when those instruments were known
to measure the same underlying construct of tinnitus symptom
severity (high convergent validity) and showed a similar direction
of treatment-related effect. We planned to take the same approach
for secondary outcomes.
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Network meta-analysis
We had planned to perform a network meta-analysis to assess the
connection between the interventions for each outcome but the
data from the included studies were inadequate.
Subgroup analysis and investigation of heterogeneity
We panned to carry out subgroup analyses to explore the potential
effect modifiers of hearing loss, baseline tinnitus symptom severity
and baseline anxiety or depression. However, insufficient data were
available.
Sensitivity analysis
We planned to conduct a sensitivity analysis by excluding those
studies with a high risk of bias, thereby checking the robustness
of the conclusion from the studies included in the meta-analysis.
However, only three studies were included in the meta-analysis,
all with similar, non-significant estimates of effect. We judged
two out of three studies (both by the same authors: Henry 2015
and Henry 2017) to have a high risk of bias, therefore sensitivity
analysis could not be performed.
GRADE and ’Summary of findings’ table
Two authors (MS and JX) independently used the GRADE ap-
proach to rate the overall quality of evidence using GRADEpro
GDT ( https://gradepro.org/). The quality of evidence reflects the
extent to which we are confident that an estimate of effect is correct
and we applied this in the interpretation of results. The quality
of evidence can be high, moderate, low or very low. High-quality
evidence implies that we are confident in our estimate of effect and
that further research is very unlikely to change our confidence in
the estimate of effect. Very low-quality evidence implies that any
estimate of effect obtained is very uncertain.
The GRADE approach can downgrade the quality of evidence for
RCTs from high to moderate, low or very low for the following
factors:
• study limitations (risk of bias);
• inconsistency;
• indirectness of evidence;
• imprecision;
• publication bias.
We planned to include ’Summary of findings’ tables, constructed
according to the recommendations described in the Cochrane
Handbook for Systematic Reviews of Interventions (Handbook
2011), for the following main comparison(s):
• Amplification only versus waiting list control, placebo,
education/information only with no device.
• Sound generator only versus waiting list control, placebo,
education/information only with no device.
• Combination devices versus waiting list control, placebo,
education/information only with no device, amplification only,
sound generator only.
However, no data were available for these main comparisons.
We did include ’Summary of findings’ tables for the two additional
comparisons for which data were available:
• Combination hearing aid versus hearing aid.
• Hearing aid versus sound generator.
We included the following outcomes in the ’Summary of findings’
tables:
• tinnitus symptom severity;
• significant adverse effect (increase in self-reported tinnitus
loudness);
• depressive symptoms;
• symptoms of generalised anxiety;
• health-related quality of life;
• other adverse effects associated with wearing the device.
R E S U L T S
Description of studies
Results of the search
Our electronic database search on 23 July 2018 identified 2527
records, of which 1202 remained after removing duplicates. We
discarded 1173 records based on title and/or abstract. We retrieved
29 records for full-text assessment. We excluded 17 studies because
they were not randomised controlled trials (n = 11) or because the
intervention or control used did not meet the criteria pre-defined
in the protocol (n = 6) (see Excluded studies).
Two records were ongoing clinical trials (see below). Two records
supplemented the methodological information that was extracted
for two included studies (NCT01857661 trial registration for dos
Santos 2014; Hazell 1985 paper for Stephens 1985).
In total, eight completed studies met our inclusion criteria (dos
Santos 2014; Erlandsson 1987; Henry 2015; Henry 2017; Melin
1987; Parazzini 2011; Stephens 1985; Zhang 2013). Three of
these studies reported quantitative data that were included in meta-
analyses (dos Santos 2014; Henry 2015; Henry 2017).
We identified no additional records from other sources. A
flowchart of study retrieval and selection is provided in Figure 1.
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Figure 1. Study flow diagram.
13Sound therapy (using amplification devices and/or sound generators) for tinnitus (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Included studies
See Characteristics of included studies.
We included eight published studies (dos Santos 2014; Erlandsson
1987; Henry 2015; Henry 2017; Melin 1987; Parazzini 2011;
Stephens 1985; Zhang 2013).
Design
Seven studies were parallel-group RCTs (dos Santos 2014; Henry
2015; Henry 2017; Melin 1987; Parazzini 2011; Stephens
1985; Zhang 2013) and one was a randomised cross-over trial
(Erlandsson 1987). Stephens 1985 was a randomised sub-study
(two separated trials) within a multi-centre study evaluating sound
generator devices (Stephens 1985, Hazell 1985 paper).
Two of the included studies had more than two treatment arms.
Henry 2017 was a three-arm trial comparing standard hearing aids,
extended wear hearing aids (EWHA) and combination hearing
aids. Stephens 1985 reported results of two three-arm trials. One
compared two types of sound generator device to counselling in
participants who did not report hearing difficulties, and the other
compared hearing aids, sound generator devices and combination
hearing aids in participants who reported hearing difficulties.
Sample sizes
The total sample size for all included studies was 590 (range 21 to
154 participants).
Setting
Two studies were set in Veterans Affairs clinics in the USA (Henry
2015; Henry 2017), three in university hospital clinics in Brazil,
Sweden and China (dos Santos 2014; Melin 1987; Zhang 2013),
one in a hospital ENT department in the UK (Stephens 1985),
one in a hospital audiology department in Sweden (Erlandsson
1987), and one in two tinnitus clinics in Italy and USA (Parazzini
2011).
Participants
All studies recruited adult participants (18 years or over). The
mean age of participants in the included studies ranged from 38.8
to 74.4 years. Mean age was not reported in Stephens 1985.
Forty-four percent of participants were women and 56% were
men. Men accounted for between 33% and 81% of participants,
depending on the study. Three studies had a larger proportion of
men than women (Erlandsson 1987; Henry 2015; Henry 2017;
81%, 73% and 78% respectively), and one had a larger proportion
of women (Melin 1987; 66%).
All studies recruited patients with hearing loss and/or perceived
hearing difficulties, with Stephens 1985 recruiting an additional
group of participants without perceived hearing difficulties (the
actual hearing status of that group was not reported). Zhang
2013 specifically recruited participants with moderate to severe
hearing loss, dos Santos 2014 recruited participants with mild to
moderate hearing loss, and Parazzini 2011 had a specific hearing
loss eligibility criterion of < 25 dB at 2 kHz and > 25 dB at
frequencies higher than 2 kHz (i.e. bordering between Categories
1 and 2 according to the TRT classification, Jastreboff 2000).
Individual tinnitus duration ranged from three months to over 20
years. Tinnitus duration was not reported in Henry 2017. Most
studies specified an inclusion criterion that considered tinnitus
symptom severity, namely high impact on life (Parazzini 2011),
bothersome tinnitus (Henry 2017), clinically significant tinnitus
(Henry 2015), tinnitus as a major problem and main symptom
(Stephens 1985), tinnitus affecting work and life (Zhang 2013),
and minimum THI score above 20 (indicating mild handicap;
dos Santos 2014). Melin 1987 and Erlandsson 1987 did not spec-
ify any inclusion criterion based on tinnitus symptom severity.
Melin 1987 classified participants according to a three-point sever-
ity grading, where a majority of participants were graded 1 (audi-
ble only in quiet environment) and 2 (audible in ordinary but not
in noisy environments; not noticeable in specific situations, such
as when the attention is focused on interesting work etc.; occa-
sionally causes disturbances in sleep), with only two participants
graded 3 (constantly noticed in all ordinary acoustical environ-
ments and causing severe disturbances of concentration and con-
tinuous disturbance of sleep). Erlandsson 1987 described eligible
participants as “clinically judged to have severe tinnitus and to be
in need of treatment”. Two studies reported mean baseline THI
scores, with both reporting mean handicap to be in the moderate
to severe range (mean THI scores = 53.2 and 59.0; dos Santos
2014; Parazzini 2011, respectively). Two studies reported mean
baseline TFI scores, with both reporting the score indicating tinni-
tus to be a “big problem” (mean TFI scores = 56.1 to 60.5; Henry
2015; Henry 2017, respectively).
Baseline anxiety and/or depression scores were not reported in
any of the included studies. Four studies had eligibility criteria
regarding mental and emotional state. Henry 2017 included par-
ticipants reporting being in good mental, emotional and health
conditions. Henry 2015 included participants with no mental,
emotional or health conditions that would prevent participating
in the study who in addition passed the Mini-Mental State Ex-
amination. Zhang 2013 excluded participants with severe mental
illness, and the inclusion criterion was tinnitus that affects work
and life, such as affecting sleep and work, causes anxiety or de-
pression, etc. Stephens 1985 excluded participants undergoing in-
tensive psychiatric treatment. Two studies accepted participants
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with anxiety/depression. In Parazzini 2011, about 20% to 30% of
participants were on medication for unrelated conditions, includ-
ing for pre-existing anxiety, depression and sleep problems. Three
studies did not mention anxiety/depression in their eligibility cri-
teria (dos Santos 2014; Erlandsson 1987; Melin 1987).
Interventions and comparisons
Seven included studies investigated the effects of hearing aids (dos
Santos 2014; Henry 2015; Henry 2017; Melin 1987; Parazzini
2011; Stephens 1985; Zhang 2013), four combination hearing
aids (dos Santos 2014; Henry 2015; Henry 2017; Stephens 1985),
and three sound generator devices (Erlandsson 1987; Parazzini
2011; Stephens 1985). Four studies included the main comparisons
specified in our protocol (Sereda 2018):
Amplification only versus waiting list control or placebo or
education/information only with no device
One study compared a hearing aid group to waiting list controls
(Melin 1987), and one compared a group fitted with hearing aids
and practising relaxation at home to a group who only practised
relaxation at home (Zhang 2013). Participants in Zhang 2013 were
fitted with hearing aids manufactured by GN ReSound, Denmark,
although the type of devices was not specified by Melin 1987. The
majority of participants in Melin 1987 were fitted bilaterally (n =
18) with only two fitted unilaterally. The number of devices (one
or two) was not reported by Zhang 2013. Both groups in Zhang
2013 practiced relaxation twice daily for 10 to 20 minutes, usually
in the morning and before sleeping.
Sound generator only versus waiting list control or placebo
or education/information only with no device
One study compared sound generator devices to placebo devices
(Erlandsson 1987), and one compared two types of sound genera-
tor device to counselling (Stephens 1985). Erlandsson 1987 used
sound generator devices constructed specifically for the study, and
sound stimulation was delivered unilaterally. Two types of sound
generator devices in Stephens 1985 were A&M masker and Vien-
natone masker, and all were fitted unilaterally.
Combination device versus waiting list control or placebo or
education/information only with no device
No studies compared combination devices to waiting list control
or placebo or education/information only.
Six studies included additional comparisons:
Hearing aids versus sound generators
Two studies compared hearing aids to sound generator devices
(Parazzini 2011; Stephens 1985). Parazzini 2011 fitted partici-
pants with bilateral open-ear hearing aids or with bilateral sound
generator devices. All hearing aids were the ’ResoundAir’ device
(GN Resound), programmed according to standard audiological
practice. All sound generator devices were behind-the-ear open
fit ’Silent Star’ devices (Viennatone) which produce a broadband
sound. All patients received the same educational counselling com-
ponent of TRT, with follow-up to optimise the therapy at 3, 6 and
12 months. Stephens 1985 compared hearing aids to sound gen-
erator devices as part of a three-arm trial (the third group received
combination hearing aids). Patients reporting hearing disability
were fitted with a standard National Health Service (NHS) be-
hind the ear hearing aid or A&M tinnitus masker. All sound gen-
erator devices were fitted unilaterally, but hearing aids were fitted
unilaterally or bilaterally, according to normal clinical indications.
Those fitted with devices all received similar counselling.
Combination hearing aids versus hearing aids
Four studies compared combination hearing aids to hearing aids
(dos Santos 2014; Henry 2015; Henry 2017; Stephens 1985). dos
Santos 2014 compared bilateral hearing aids with integrated sound
generator devices developed by the Department of Otolaryngol-
ogy of the University of São Paulo in two modes: a combined
mode (amplification and sound generation activated) and a simple
mode (amplification only). Henry 2015 fitted participants bilater-
ally with “commercially available” receiver-in-the-canal combina-
tion hearing aids with the sound generator activated or not (am-
plification only). Henry 2017 compared combination hearing aids
to two brands of hearing aids (amplification only). Combination
hearing aids were Audeo Q (Phonak) receiver-in-the-canal devices
with the sound generator activated. Hearing aids (amplification
only) were Audeo Q (Phonak) hearing aids and EWHA; Lyric
(Phonak). All three groups received education, which took place
following device fitting and adjustment. In the study by Stephens
1985, patients reporting hearing disability were allocated to a stan-
dard NHS behind the ear hearing aid (n = 26), Danavox 775-PP-
AGC/masker module combination hearing aid (n = 23), or A&
M sound generator device (n = 23). All sound generator devices
were fitted unilaterally, but hearing aids were fitted unilaterally or
bilaterally, according to normal clinical indications. Those fitted
with devices all received similar counselling.
Combination hearing aids versus sound generators
One study compared combination hearing aids to sound gener-
ators (Stephens 1985). Patients reporting hearing disability were
fitted with Danavox 775-PP-AGC/masker module combination
hearing aid or A&M sound generator device. All devices were fit-
ted unilaterally. Those fitted with instruments all received similar
counselling.
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Outcomes
Primary outcomes
Four studies reported changes in tinnitus symptom severity before
and after treatment as measured by the global score on a multi-
item questionnaire (dos Santos 2014; Henry 2015; Henry 2017;
Parazzini 2011). dos Santos 2014 and Parazzini 2011 used the
Tinnitus Handicap Inventory (THI) (Table 1; Newman 1996).
Henry 2015 and Henry 2017 used the Tinnitus Functional Index
(TFI) (Table 1; Meikle 2012). Outcomes were measured at three
months (dos Santos 2014), three to four months (Henry 2015),
four to five months (Henry 2017), and three, six and 12 months
(Parazzini 2011).
Serious adverse effects were not assessed in any of the included
studies.
Secondary outcomes
Stephens 1985 measured anxiety, phobic anxiety, somatic anxiety
and depression using the subscales of the Crown Crisp Experien-
tial Index (data for the randomised and non-randomised groups
pooled together are available in Stephens 1985, Hazell 1985 pa-
per), however data for the randomised part of the study were not
reported in the manuscript (Stephens 1985), and we were not able
to contact the authors to obtain the data.
Health-related quality of life was not measured in the included
studies.
Adverse effects were not assessed in the included studies.
Other core outcomes
None of the studies measured the newly developed core outcomes
for trials of sound therapy: tinnitus intrusiveness, ability to ignore,
concentration, quality of sleep or sense of control.
Non-relevant outcomes
Three studies did not use any outcome measures relevant to this re-
view (Types of outcome measures) (Erlandsson 1987; Melin 1987;
Zhang 2013). Erlandsson 1987 reported a 10-point visual ana-
logue scale of tinnitus intensity, usage, specific effects (self-rated
changes in tinnitus intensity and in the degree of negative reactions
to tinnitus) and non-specific effects (self-rated changes of mood,
stress, somatic symptoms other than tinnitus and medication).
Melin 1987 reported a visual analogue scale (10 cm, unmarked)
assessing tinnitus and hearing ability in four different hearing sit-
uations using a semi-structured interview. Zhang 2013 assessed
tinnitus symptom severity using a single item with four categories
of therapeutic effect: (i) complete adaptation: tinnitus symptom
disappears or significantly relieves, with normal emotion, sleeping,
work and life; (ii) basic adaptation: tinnitus symptom disappears,
relieves or still exists, but with normal emotion, sleeping, work
and life; (iii) partial adaptation: tinnitus still exists, partially affect-
ing emotion, sleeping, work and life; (iv) no adaptation: tinnitus
symptom still exists or even worse, seriously affecting emotion,
sleeping, work and life.
Excluded studies
We excluded a total of 17 studies. We excluded 11 studies because
they were not RCTs (Al-Jassim 1988; Andersson 2002; Benton
2016; Del Bo 2006; Gudex 2009; Hernández Moñiz 1998; Hiller
2005; Lipman 2007; Mehlum 1984; Shabana 2018; Sweetow
2010). We excluded six studies because of the intervention or
control they used (Durai 2017; Henry 2016; Hodgson 2017;
Strauss 2015; Tao 2017; Thedoroff 2017). See Characteristics of
excluded studies for details.
Ongoing studies
Two records identified in our search are ongoing clinical tri-
als, which are reported in Characteristics of ongoing studies
(ISRCTN15178771; TCTR20180225002).
Risk of bias in included studies
We assessed risk of bias based on the information provided in
the published reports. See Figure 2 and Figure 3 for a graph and
summary of risk of bias across studies.
16Sound therapy (using amplification devices and/or sound generators) for tinnitus (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Random sequence generation
We considered the risk of selection bias due to inadequate se-
quence generation to be unclear in six studies (dos Santos 2014;
Erlandsson 1987; Henry 2015; Melin 1987; Stephens 1985;
Zhang 2013). We judged the remaining two studies to have
a low risk of bias (Henry 2017; Parazzini 2011). Henry 2017
achieved random sequence generation using computer software
and Parazzini 2011 stated that “randomisation was obtained on
the basis of a random table”.
Allocation concealment
We judged Henry 2017 to have low risk of bias as allocation
concealment was achieved using sequentially numbered, opaque,
sealed envelopes, which were opened by study staff to randomise
and enrol participants. For the remaining seven studies, risk of bias
due to allocation concealment was unclear as the information was
not reported (dos Santos 2014; Erlandsson 1987; Henry 2015;
Melin 1987; Parazzini 2011; Stephens 1985; Zhang 2013).
Blinding
Blinding of participants and personnel
The blinding of participants was not possible in any of the studies
because the groups received visibly different interventions (device
or no device, different types of devices). Blinding of personnel was
not attempted in seven studies and therefore we judged the risk
of bias to be high (Erlandsson 1987; Henry 2015; Henry 2017;
Melin 1987; Parazzini 2011; Stephens 1985; Zhang 2013). For
dos Santos 2014, only in the trial registration was it stated that the
initial and final evaluation of the primary outcome was performed
by an investigator who was blinded to group allocation and so we
rated the risk of bias as unclear.
Blinding of outcome assessment
We judged two studies to have a high risk of bias due to lack of
blinding of outcome assessments (Henry 2015; Stephens 1985). In
dos Santos 2014, the initial and final evaluations were performed
by a blind evaluator and so we judged the risk of bias to be low.
In five studies, the risk of performance bias and detection bias as a
result of inadequate blinding was unclear (Melin 1987; Erlandsson
1987; Henry 2017; Parazzini 2011; Zhang 2013).
Incomplete outcome data
We judged Erlandsson 1987 to have high risk of bias due to incom-
plete outcome data. The authors reported that data were omitted
for four participants because of inadequate use (not specified) of
rating scales and that data for “specific and non-specific effects” for
two participants were incomplete due to “a lack of cooperation”
(not explained). Handling of missing data was not described.
We judged Parazzini 2011 and Stephens 1985 to have unclear risk
of bias. In Parazzini 2011, 10 participants out of 101 were excluded
due to missing recordings, however no additional explanation was
included. Structured interview data were recorded, analysed and
reported for the subset of 51 out of 91 participants only. For
Stephens 1985, a full description of the study provided in Stephens
1985, Hazell 1985 paper, reports 153 patients starting the study
and 119 reaching the first evaluation. However, data from only 147
participants were reported in Stephens 1985. Dropout between
the start of the study and the first evaluation was not explained.
We judged five studies to have low risk of bias due to incomplete
outcome data as all participant data were reported or reasons for
dropout were explained (dos Santos 2014; Henry 2015; Henry
2017; Melin 1987; Zhang 2013).
Selective reporting
We identified one study protocol for the included studies, namely
a prospective trial registration that was available for dos Santos
2014. We judged this study to have a low risk of bias due to selective
reporting as all pre-specified outcome measures were reported. In
five studies, the outcomes that were mentioned in the abstract
and/or methods section were also reported in the results section
and therefore we considered the risk of selective reporting to be
low in these studies (Henry 2015; Henry 2017; Parazzini 2011;
Stephens 1985; Zhang 2013).
We judged two studies to have unclear risk of bias (Erlandsson
1987; Melin 1987). Erlandsson 1987 did not report between-
group differences at six weeks, after the first part of a cross-over
trial. Melin 1987 did not report any dropout for the experimental
period and it was unclear if all interview data were reported.
Other potential sources of bias
Conflict of interest was not reported in five studies (Erlandsson
1987; Henry 2017; Melin 1987; Stephens 1985; Zhang 2013),
and funding was not reported in one study (Henry 2017). As
Henry 2017 did not report either conflict of interest or funding
we judged the risk of bias as unclear. We judged Stephens 1985 to
have high risk of bias due to reported differences between two ther-
apists conducting the study and because only some of the patients
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underwent a full neuro-otological examination. For seven stud-
ies there was no prospective protocol available (Erlandsson 1987;
Henry 2015; Henry 2017; Melin 1987; Parazzini 2011; Stephens
1985; Zhang 2013). No other sources of bias were identified for
the remaining studies.
Effects of interventions
See: Summary of findings for the main comparison Hearing aid
compared to sound generator for tinnitus in adults; Summary of
findings 2 Combination hearing aid compared to hearing aid for
tinnitus in adults
See Summary of findings for the main comparison; Summary of
findings 2.
Data from Erlandsson 1987, Melin 1987, Parazzini 2011,
Stephens 1985 and Zhang 2013 were not included in the meta-
analysis (see Characteristics of included studies).
No data were available for any of our three main comparisons:
’Hearing aid only versus waiting list control or placebo or edu-
cation/information only with no device’; ’Sound generator device
only versus waiting list control or placebo or education/informa-
tion only with no device’; ’Combination hearing aid versus wait-
ing list control or placebo or education/information only with no
device’.
Data were available only for the additional comparisons: ’Hearing
aid only versus sound generator device only’ and ’Combination
hearing aid versus hearing aid only’.
Hearing aid only versus waiting list control or placebo
or education/information only with no device
Two studies made this comparison (Melin 1987; Zhang 2013).
Primary outcomes
Tinnitus symptom severity
Tinnitus symptom severity measured with a multi-item question-
naire was not reported.
Significant adverse effects
Significant adverse effects of self-reported increase in tinnitus loud-
ness were not reported.
Secondary outcomes
No secondary outcomes relevant to this review were reported.
Additional (core) outcomes
No additional outcomes relevant to this review were reported.
Sound generator device only versus waiting list
control or placebo or education/information only
with no device




Tinnitus symptom severity measured with a multi-item question-
naire was not reported.
Significant adverse effects
Significant adverse effects of self-reported increase in tinnitus loud-
ness were not reported.
Secondary outcomes
No secondary outcomes relevant to this review were reported.
Additional (core) outcomes
No additional outcomes relevant to this review were reported.
Combination hearing aid versus waiting list control or
placebo or education/information only with no device
None of the included studies made this comparison.
Hearing aid only versus sound generator device only




Parazzini 2011 reported tinnitus symptom severity as measured
using the Tinnitus Handicap Inventory (THI) at three, six and
12 months. Parazzini 2011 reported no statistically significant dif-
ference in change in tinnitus symptom severity between groups.
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We estimated mean values from the data plots. For patients who
were fitted with hearing aids, the THI score reduced from ~58.9
to ~40.0 points at three months, ~33.3 at six months and ~28.8
at 12 months. The group who received sound generators reported
a reduction from ~56.8 to ~36.6 points at three months, ~33 at
six months and ~27.6 at 12 months. Parazzini 2011 performed a
two-way ANOVA showing that the reduction in THI was statis-
tically significant overall (P < 0.001). However, there was no clear
difference between groups at three, six or 12 months. The mean
difference was 1.30 (95% confidence interval (CI) -5.72 to 8.32)
at three months, -1.80 (-8.82 to 5.22) at six months and -0.90
(95% CI -7.92 to 6.12) at 12 months (Analysis 1.1; Analysis 1.2;
Analysis 1.3). The reduction in THI score was clinically signifi-
cant (i.e. more than 20 points, Newman 1996) at three, six and 12
months for the sound generator group and at six and 12 months
for the hearing aid group.
Using GRADE we assessed the quality of evidence for tinnitus
symptom severity at three months, six months and 12 months as
low.
Significant adverse effects
Significant adverse effects of self-reported increase in tinnitus loud-
ness were not reported.
Secondary outcomes
No secondary outcomes relevant to this review were reported.
Additional (core) outcomes
No additional outcomes relevant to this review were reported.
Combination hearing aid versus hearing aid only
Four studies made this comparison (dos Santos 2014; Henry 2015;
Henry 2017; Stephens 1985).
Primary outcomes
Tinnitus symptom severity
Three studies measured tinnitus symptom severity. dos Santos
2014 used the THI, while Henry 2015 and Henry 2017 used
the Tinnitus Functional Index (TFI). Henry 2015 reported TFI
scores with and without the devices, but we have included only
scores with the devices in the analysis for consistency with the
other included studies. For Henry 2017, we included only two
groups in the meta-analysis (combination hearing aids and con-
ventional hearing aids) and excluded the extended wear hearing
aids (EWHA) group as it was not directly comparable to the other
hearing aids used in the included studies. For Henry 2015, no
standard deviation for the mean change was reported and so we
used the standard deviation from another study by the same au-
thor (Henry 2017) as a reasonable alternative. There was no clear
difference between the hearing aid and combination hearing aid
groups. The pooled standardised mean difference was -0.15 (95%
CI -0.52 to 0.22; low-quality evidence; Analysis 2.1; Figure 4).
Outcomes were measured at three months (dos Santos 2014), three
to four months (Henry 2015), and four to five months (Henry
2017).
Figure 4. Forest plot of comparison: 2 Combination hearing aid versus hearing aid, outcome: 2.1 Tinnitus
symptom severity.
Significant adverse effects
Significant adverse effects of self-reported increase in tinnitus loud-
ness were not reported.
Secondary outcomes
No secondary outcomes relevant to this review were reported.
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Additional (core) outcomes
No additional outcomes relevant to this review were reported.
Combination hearing aid versus sound generator only
One study made this comparison (Stephens 1985).
Primary outcomes
Tinnitus symptom severity
Tinnitus symptom severity measured with a multi-item question-
naire was not reported.
Significant adverse effects
Significant adverse effects of self-reported increase in tinnitus loud-
ness were not reported.
Secondary outcomes
No secondary outcomes relevant to this review were reported.
Additional (core) outcomes
No additional outcomes relevant to this review were reported.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Combination hearing aid compared to hearing aid for tinnitus in adults
Patient or population: adults with subject ive idiopathic t innitus
Setting: Veterans Af fairs clinic (2 studies), university hospital clinic (1 study)
Intervention: combinat ion hearing aid
Comparison: hearing aid














(1 study) and Tinni-
tus Funct ional Index (2
studies)
Scale f rom: 0 to 100
Follow-up: range 3
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ciated with wearing the
device (such as pain,
discomfort , tenderness
or skin irritat ion, or ear
infect ions)
Not measured
CI: conf idence interval; SMD: standardised mean dif ference
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Serious risk of bias due to lack of blinding of part icipants, personnel and outcome assessments as well as select ion bias.















































































































D I S C U S S I O N
Summary of main results
The objective of this review was to assess the effects of sound
therapy (using amplification devices and/or sound generators) for
acute (≤ 3 months) or chronic (> 3 months) subjective idiopathic
tinnitus in adults. This review includes eight studies (590 partic-
ipants). Seven studies investigated the effects of hearing aids (dos
Santos 2014; Henry 2015; Henry 2017; Melin 1987; Parazzini
2011; Stephens 1985; Zhang 2013), four combination hearing
aids (dos Santos 2014; Henry 2015; Henry 2017; Stephens 1985),
and three sound generators (Erlandsson 1987; Parazzini 2011;
Stephens 1985).
Only four studies reported outcome measures and comparisons
of interest to this review and no data were available for any of
our three main comparisons: hearing aid only/sound generator
device only/combination hearing aid versus waiting list control or
placebo or education/information only with no device. One study
compared patients fitted with sound generators versus those fitted
with hearing aids (Parazzini 2011), finding no difference between
them in the effects on our primary outcome, tinnitus symptom
severity (Summary of findings for the main comparison). The use
of both types of devices was associated with a clinically significant
reduction in tinnitus symptom severity. In summary, hearing aids
were not better or worse than sound generators. No evidence was
found in this study for the other outcomes of interest in this review.
Three studies compared combination hearing aids with hearing
aids (dos Santos 2014; Henry 2015; Henry 2017). These studies
found no difference between them in their effects on the change
in tinnitus symptom severity (Summary of findings 2). The use
of both types of devices was associated with a clinically significant
reduction in tinnitus symptom severity. In summary, hearing aids
were not better or worse than combination hearing aids. No evi-
dence was found in these studies for the other outcomes of interest
in this review.
There is insufficient evidence to support the superiority or infe-
riority of any of the sound therapy options (hearing aid, sound
generator or combination hearing aid) over each other. There is no
evidence to support the superiority of sound therapy for tinnitus
over waiting list control, placebo or education/information with
no device.
Overall completeness and applicability of
evidence
All of the included studies included patients with subjective id-
iopathic tinnitus. All studies included patients with a minimum
duration of tinnitus of at least three months. No studies included
only patients with acute tinnitus (≤ 3 months). All studies re-
cruited patients with hearing loss and/or perceived hearing diffi-
culties.
Six out of the eight included studies specified eligibility crite-
ria concerning tinnitus symptom severity. Five studies used de-
scriptive criteria of high impact on life (Parazzini 2011), bother-
some tinnitus (Henry 2017), clinically significant tinnitus (Henry
2015), tinnitus as a major problem and main symptom (Stephens
1985), and tinnitus affecting work and life (Zhang 2013). One
study used a criterion based on a Tinnitus Handicap Inventory
(THI) score of 20 or more, but the mean baseline THI in the in-
cluded population was higher than this, being in the moderate to
severe range (Parazzini 2011). Melin 1987 and Erlandsson 1987
did not specify eligibility criteria concerning tinnitus symptom
severity. Melin 1987 classified recruited participants according to
a three-point severity grading system, where a majority of par-
ticipants fell within grades 1 and 2. Erlandsson 1987 described
included participants as “clinically judged to have severe tinnitus
and to be in need of treatment”.
Baseline anxiety and/or depression scores were not reported in
the included studies. Some studies had inclusion criteria regard-
ing mental and emotional state: Henry 2017 included partici-
pants reporting as being in good mental, emotional and health
conditions, Henry 2015 included participants with no mental,
emotional or health conditions that would prevent participation
in the study who in addition passed the Mini-Mental State Ex-
amination, Zhang 2013 excluded participants with severe mental
illness, and Stephens 1985 excluded participants undergoing in-
tensive psychiatric treatment. However, two studies specified that
they accepted participants with anxiety/depression. In Parazzini
2011, about 20% to 30% of participants were on medication for
unrelated conditions, including pre-existing anxiety, depression
and sleep problems. In Zhang 2013, the inclusion criterion was
tinnitus that affects work and life, such as affecting sleep and work,
causing anxiety or depression, etc. Three studies did not mention
anxiety/depression in their inclusion criteria and did not report
anxiety/depression scores in the baseline characteristics of partici-
pants (dos Santos 2014; Erlandsson 1987; Melin 1987).
The study dos Santos 2014 used combination hearing aids that
were developed by the Department of Otorhinolaryngology of
the University of São Paulo and therefore might not be directly
comparable to commercially available devices. Two studies used
devices by specific manufacturers only (Henry 2015; Henry 2017).
Only four studies reported our pre-specified outcome measures.
Among these only tinnitus symptom severity measured with a
standardised instrument was reported. Different instruments were
used to assess tinnitus symptom severity. Two studies used the
THI (dos Santos 2014; Parazzini 2011) and two the Tinnitus
Functional Index (TFI) (Henry 2015; Henry 2017). All studies
assessed tinnitus symptom severity at three to six months from
baseline, with one study also conducting follow-up at 12 months
(Parazzini 2011).
Adverse effects were not assessed in any of the included studies.
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Quality of the evidence
For the comparison ’Combination hearing aids versus hearing aids’
the quality of evidence for the primary outcome, tinnitus symptom
severity, was low. We downgraded the quality of evidence by two
levels due to serious risk of bias and imprecision. Serious risk of
bias presented as a lack of blinding of participants, personnel and
outcome assessors, as well as selection bias. Serious imprecision
presented as a wide confidence interval showing a small benefit
and a moderate harm.
For the comparison ’Hearing aids versus sound generators’ the
quality of evidence for tinnitus symptom severity at three months,
six months and 12 months was low. For all outcomes, we down-
graded the quality of the evidence by two levels due to serious risk
of bias and imprecision. Serious risk of bias presented as a lack of
blinding of participants and personnel, unclear risk of bias for al-
location concealment, blinding of outcome assessors, and attrition
bias. Serious imprecision presented as a wide confidence interval
showing a substantial benefit and a substantial harm.
Potential biases in the review process
Our searches of the electronic databases were comprehensive. We
also searched the reference lists of the included studies and previous
Cochrane Reviews (Hoare 2014; Hobson 2012). Language was
not a barrier to inclusion and, in addition to English, we reviewed
full-text articles in Chinese and Spanish for eligibility assessment.
All author roles were pre-defined in the review process. We adhered
to a pre-published protocol and no post hoc decisions or changes
were made.
Agreements and disagreements with other
studies or reviews
This is a new review, superseding two previous Cochrane Reviews
on sound therapy (masking) and on amplification with hearing
aids for tinnitus that were first published in the Cochrane Library
in Issue 12, 2010 and updated in 2012 (Hobson 2012) and in
Issue 1, 2014 (Hoare 2014), respectively. Hobson 2012 included
six studies that varied in design, with significant heterogeneity
in the evaluation of subjective tinnitus perception, with different
scores, scales, tests and questionnaires as well as variance in the
outcome measures used to assess the improvement in tinnitus sen-
sation/quality of life. Due to this variability meta-analysis was not
conducted. The main difference between Hobson 2012 and the
current review regards the inclusion criteria, as the current review
excluded studies evaluating complex interventions, which explic-
itly included a sound therapy and other non-sound components
(e.g. psychotherapy) as a part of a programme (e.g. Neuromon-
ics). Therefore only one study included in Hobson 2012 was also
included in this review. Similar to our review, Hobson 2012 con-
cluded that the limited data from the included studies showed that
sound therapy on its own is of unproven benefit in the treatment
of tinnitus. As with the current review, Hoare 2014 included only
one randomised controlled trial (RCT) that is also included in
this review, comparing amplification only (hearing aid) to a sound
generator (Parazzini 2011), and found no difference between the
two interventions. No studies comparing hearing aids to placebo
or no intervention were identified.
In 1999 a broad systematic review mapped out the evidence for
the therapeutic efficacy of known promising interventions that
deserve further research, considering reports of all RCTs of any
tinnitus intervention (Dobie 1999). That review included two
RCTs looking at ’masking’ (Erlandsson 1987; Stephens 1985; both
also included in this review). Neither of those studies reported
outcome measures pre-specified for the current review, therefore
we were not able to derive any conclusions regarding sound therapy
based on those studies.
A systematic review and meta-analysis by Hoare 2011b included
one study (Stephens 1985; also included in this review). This in-
volved groups of participants with hearing aids, sound generators
and combination devices, compared to limited counselling with no
device, described in the context of sound enrichment therapy. The
review reported no improvements in this study, with one group
using sound generators reporting a significant increase in anxiety
(measured with the Crown Crisp Experiential Index) compared to
controls. The study by Stephens 1985 did not report any of the
outcome measures of interest for the current review, therefore we
were not able to derive any conclusions regarding sound therapy
based on this study.
In summary, similar to the current review, previous reviews have
concluded that there is no evidence of a therapeutic benefit of
sound therapy for tinnitus.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Sound therapy is the preferred mode of audiological tinnitus man-
agement in many countries, including the United Kingdom (Hall
2011). Postulated mechanisms through which sound therapy can
be beneficial for tinnitus include reducing tinnitus intrusiveness,
aiding habituation, distracting attention from tinnitus and trigger-
ing neuroplasticity within the brain (Hoare 2014a). However, we
did not find evidence to support or refute the provision of sound
therapy as the primary intervention for people with tinnitus. We
did not find evidence to suggest that one type of sound therapy
device (i.e. hearing aid, sound generator or combination hearing
aid) is better than others. However, there were also no reports of
adverse effects in the included studies.
In line with the lack of evidence for the effectiveness of sound ther-
apy current tinnitus management guidelines do not make strong
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recommendations regarding its use in clinical practice and allow
patients’ preferences to play a significant role in the choice of this
management option (Cima 2018; Tunkel 2014). The American
Academy of Audiology Clinical Practice Guideline recommends
that clinicians should offer a hearing aid evaluation for patients
with hearing loss and persistent, bothersome tinnitus (Tunkel
2014). This recommendation was informed by findings from ob-
servational studies with a preponderance of benefit over harm
and by the lack of high-quality evidence. Highlighted benefits of
amplification in patients with hearing loss and tinnitus were im-
provement in communication function and health-related quality
of life with “potential benefit for tinnitus relief ”. While a recent
Cochrane Review found evidence of improvements in commu-
nication and general health-related quality of life in people with
mild to moderate hearing loss (Ferguson 2017), the current review
did not find evidence of benefit for tinnitus. More in line with the
evidence presented here, the Multidisciplinary European Guide-
line for Tinnitus recommends hearing aids for the management of
hearing loss and that they should be considered as an option for
patients with tinnitus and hearing loss, but should not be offered
to patients with tinnitus but without hearing loss (Cima 2018).
With regard to other sound therapy options, namely sound genera-
tors and combination hearing aids, neither Tunkel 2014 nor Cima
2018 made a recommendation because they judged the strength
of evidence for effectiveness to be low. This is very much in line
with the findings of this review. Tunkel 2014 stated that clini-
cians might recommend sound therapy to patients with persis-
tent, bothersome tinnitus, with a significant role for the patient in
deciding whether to pursue sound therapy and choosing among
the available options. Cima 2018 concluded that sound therapy
may be useful for the purposes of acute tinnitus relief but did not
consider it to be effective over the long term.
Implications for research
Future research into the effectiveness of sound therapy in patients
with tinnitus should use rigorous methodology. Randomisation
and blinding should be of the highest quality, given the subjective
nature of tinnitus and the strong likelihood of a placebo response.
The CONSORT statement should be used in the design and re-
porting of future studies (CONSORT 2010).
We also recommend the use of standardised and validated, pa-
tient-centred outcome measures for research in the field of tinni-
tus. Visual analogue scales have limited value in this regard be-
cause quantifying change using only a single item has inadequate
measurement properties (e.g. internal consistency cannot be es-
tablished and test-retest scores are at greater risk of instability).
Although most recent studies included in this review used multi-
item questionnaires of tinnitus symptom severity, other outcomes
such as depressive symptoms or depression, anxiety symptoms or
generalised anxiety and health-related quality of life were not mea-
sured. None of the studies reported adverse effects. In future tri-
als, in addition to multi-item questionnaires of tinnitus symptom
severity, validated instruments measuring depression, anxiety and
health-related quality of life should also be used. Adverse effects
such as increased tinnitus loudness and adverse effects associated
with wearing the device such as pain, discomfort, tenderness, skin
irritation or ear infections should be collected and reported.
At the time of the publication of this review, core outcome mea-
sures for adults with subjective tinnitus have only recently been
identified (Hall 2018a). For sound-based interventions, these are
tinnitus intrusiveness, ability to ignore, concentration, quality of
sleep and sense of control. None of the trials directly reported
any of the core outcome measures. Use of the core outcome set
as a minimum standard for what should be assessed and reported
in randomised controlled trials will facilitate comparison between
studies and meta-analyses (Tunis 2016).
Given the heterogeneity of tinnitus patients, future trials should
assess and report baseline characteristics so that the risk of po-
tential confounding factors can be better understood. Examples
include tinnitus duration, tinnitus symptom severity, age, hearing
loss and co-morbidities since these might reasonably modify treat-
ment success. Future trials might also consider, as a subgroup anal-
ysis, the differential effect of sound therapy on acute (i.e. less that
three months duration) versus chronic (more than three months
duration) subjective idiopathic tinnitus.
Currently there are no trials that consider the effectiveness of sound
therapy for acute tinnitus. Only two included studies performed a
sample size estimation (dos Santos 2014; Henry 2017), and even
then not necessarily reaching the pre-specified targets (dos Santos
2014). Future studies should seek to recruit an adequate sample
size based on an appropriate power calculation for the primary
outcome.
Evidence for the effectiveness of hearing aids, combination aids
and sound generators compared to no intervention, placebo inter-
vention or education/information only is lacking and only a lim-
ited number of small-scale studies compared different sound ther-
apy options (hearing aids, combination hearing aids and sound
generators). Further research should concentrate on generating the
evidence for the effectiveness of each of those management op-
tions for tinnitus, followed by trials comparing the effectiveness
of different sound therapy options.
All studies included follow-up at three to six months, which
was shown to be sufficient for demonstrating improvements with
sound therapy (Hobson 2012). However, as the use of sound is
intended to alter the tinnitus perception and/or the reactions to
tinnitus, the timescale for different mechanisms of action might
be different and extend beyond that limit (Hoare 2013). Future
studies might consider including long-term follow-up in order to
explore differences in the mechanisms of action of different sound
therapy options (i.e. short- versus long-term intervention; Cima
2012) and changes in patterns of use (Sweetow 2015).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
dos Santos 2014
Methods 2-arm, single-centre, randomised, controlled (parallel) trial with 3 months duration of
treatment and 3 months duration of follow-up
Participants Setting: patients were screened and treated at the Department of Otorhinolaryngology,
University of São Paulo, Brazil
Sample size:
• Number randomised: 49
• Number completed: 47
49 participants were enrolled, but due to 2 participants lost to follow-up data from 47
participants were included in the analysis. Sample size calculations based on the Tinnitus
Handicap Inventory indicated that to achieve 80% power to detect a minimum difference
of 20 points between the groups at a two-tailed significance level of 5%, 24 participants
were required per group, totaling 48 individuals. Therefore due to excluding patients
lost to follow-up from the analysis (n = 2) the sample size was lower than required (n =
47; n = 24 and 23 per group)
Participant (baseline) characteristics:
• Age: group level data for age were not provided. The 47 participants included in
the analysis were between 26 and 91 years old
• Gender: group level data for gender were not provided. 25 women and 22 men
were included in the study.
• Other characteristics:
Group level data for laterality of tinnitus, characteristics of tinnitus and depression/
anxiety were not provided. The most frequent location of tinnitus was in both ears (n
= 18), followed by the head (n = 15) and in only one ear (n = 14). The most common
types of tinnitus were whistling (n = 9), roaring (n = 7) and buzzing (n = 6)
Group level data for participants included in the analysis for age, duration of tinnitus,
baseline tinnitus severity, psychoacoustic characteristics of tinnitus (loudness, minimum
masking level and pitch) and hearing loss were provided. The group who received com-
bination aids had a mean age of 74.4 years (SD 10.7) and the group who received hearing
aids had a mean age of 69.7 years (14.2). Mean duration of tinnitus was 12.7 years (SD
8.3) in the combination aid group and 7.6 years (SD 6.6) in the hearing aid group.
Tinnitus duration was significantly different between the 2 groups (Wilcoxon test; P =
0.02). The mean Tinnitus Handicap Inventory score was 53.2 (SD 20.5) in the combi-
nation aid group and 57.5 (SD 16.4) in the hearing aid group, numeric scale of tinnitus
discomfort score was 7.8 (SD 1.9) in both groups. Mean tinnitus loudness measured
using loudness matching was 10.2 dBSL (SD 4.7) in the combination aid group and 9
dBSL (4.5) in the hearing aid group, mean minimum masking level was 25.2 dBSL (SD
24.8) and 23.5 dBSL (SD 18.1) respectively, and mean tinnitus pitch measured with
pitch matching procedure was 5041 Hz (SD 1983) and 4773 Hz (SD 2207) respectively.
In the combination aid group 14 participants had mild and 10 moderate hearing loss;
17 had sloping and 7 flat hearing loss. In the hearing aid group 12 participants had
mild and 11 moderate hearing loss; 19 had sloping and 4 flat hearing loss. None of the
baseline measures, except tinnitus duration, were significantly different between groups
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dos Santos 2014 (Continued)
Inclusion criteria: adults (18 years and older), mild to moderate bilateral symmetrical
sensorineural hearing loss, with complaints of constant tinnitus for at least 6 months,
with THI score more than 20 points and without prior experience with hearing aids or
any other type of sound therapy
Exclusion criteria: profound hearing loss, conductive hearing loss, THI score < 20
Interventions Intervention group: combination device (n = 24)
Comparator group: amplification only (hearing aid, n = 23)
The combination hearing aid group was fitted bilaterally with hearing aids with inte-
grated sound generator developed by the Department of Otorhinolaryngology of the
University of São Paulo, in combined mode or, in other words, with the combined use
of amplification and sound generator. This was a behind-the-ear (BTE) digital hearing
aid with 16 channels of gain adjustments. It was equipped with an integrated white
noise that could be used together with the amplification mode or not. The hearing aids
group was fitted bilaterally with the same hearing aid, but in simple mode, meaning
amplification alone. The patients were advised to use the device for at least 8 hours per
day. Duration of treatment was 3 months
Use of additional interventions: both groups received the same specific counselling
about the aspects relevant to tinnitus
Outcomes Primary: tinnitus symptom severity (Tinnitus Handicap Inventory, THI)
Secondary: numeric scale of tinnitus discomfort (1 to 10) and psychometric measures of
tinnitus (tinnitus pitch obtained through pitch matching procedure, tinnitus loudness
obtained through loudness matching procedure and minimum masking level)
Outcomes were measured at 3 months
Funding sources This study was financially supported in the form of Research Grants by the Foundation
for Research Support of São Paulo state
Declarations of interest None declared
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The authors stated that participants were
randomly allocated to groups but did not
provide any details on methods: “(...) the
patients were randomly assigned into two
groups: a combined fitting group and an
amplification alone group”. The trial was
registered in clinicaltrials.gov as a ran-
domised controlled trial
Allocation concealment (selection bias) Unclear risk Information not reported in the
manuscript or trial registration
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dos Santos 2014 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Initial evaluation and final evaluation was
performed by a blind evaluator. Single
blinding (investigator) stated in the trial
registration. Participants were not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Initial evaluation and final evaluation was
performed by a blind evaluator. Single
blinding (investigator) stated in the trial
registration
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 participants did not attend the final
evaluation; reasons were reported in the
manuscript: “Of the 49 patients who took
part in the study, two did not attend the
final evaluation. One of them was not lo-
cated, and the other suffered a heart attack
which made it impossible to attend. They
were both therefore excluded from the sta-
tistical analysis for missing the follow-up.”
Selective reporting (reporting bias) Low risk Primary outcome reported in clinicaltri-
als.gov record. Additional secondary out-
comes were reported in the manuscript that
were not stated in the trial registration (nu-
meric scale of tinnitus discomfort, tinnitus
pitch, tinnitus loudness, minimum mask-
ing level)
Other bias Low risk No other biases identified. Trial regis-
tered in clinicaltrials.gov, trial identifier:
NCT01857661
Erlandsson 1987
Methods 2-arm, single-centre, cross-over randomised trial with 6 weeks duration of treatment
(primary endpoint)
Participants Setting: patients were screened and treated at the Department of Audiology, Sahlgrenska
Hospital, Göteborg, Sweden
Sample size:
• Number randomised: 21
• Number completed: 21
Participant (baseline) characteristics:
• Age: group level data for age were not provided. The 21 patients enrolled in the
study had a mean age of 51 years (range 21 to 66 years).
• Gender: group level data for age were not provided. 4 women and 17 men were
included in the study.
• Other characteristics:
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Erlandsson 1987 (Continued)
Group level data for baseline characteristics of participants were not provided. The 21
patients enrolled in the study had tinnitus for at least 1 year, reported tinnitus in left ear
(n = 7), right ear (n = 7), both ears (n = 4) or inside the head (n = 3). 13 participants
reported tonal and 7 noise tinnitus, centre frequencies ranged from 277 Hz to 8660
Hz. All participants were “clinically judged to have severe tinnitus and to be in need of
treatment”. The mean pure tone average (0.5, 1 and 2 kHz) of the treated ear was 29 dB
(SD 19.5)
Inclusion criteria: participants able to follow study instructions
Exclusion criteria: not reported
Interventions Intervention group: sound generator
Comparator group: placebo device
The masker equipment was constructed for this study and allowed frequency adjustment
between 250 Hz and 10,000 Hz and continuous variation of bandwidth between these
frequencies. Touch controls allowed the user to activate the specific sound, or a sound with
a free choice of parameters. Noise was set at the level “enough to cause total masking”.
The placebo unit called “Elstimulator (electrical stimulator)” was identical in size, with
about the same degree of variation available to the user. Duration of each treatment was
6 weeks. Overall masker use ranged from 0 to 390 minutes per day, and Elstimulator
use from 0 to 600 minutes per day
Use of additional interventions: none
Outcomes Primary: tinnitus intensity (10-point scale)
Secondary: usage, specific (self-rated changes in tinnitus intensity and in the degree
of negative reactions to it) and non-specific effects (self-rated changes of mood, stress,
somatic symptoms other than tinnitus, and medication)
Outcomes were measured after each treatment (at 6 and 12 weeks), however outcomes
after 6 weeks were not reported
Funding sources This research was supported by the Swedish Ministry of Health and Social Affairs,
Delegation for Social Research (project no. 82/120), the Swedish Council for Planning
and Coordination of Research, the National Swedish Board for Technical Development
and the Swedish Medical Research Council (project no. B 85-17X-06574)
Declarations of interest None reported
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The authors stated that participants were
randomly allocated to groups but did not
provide any details on methods: “The 21
patients were randomised into two groups
(n = 10 and 11, respectively); both groups
received both treatments but in different
order.”
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Erlandsson 1987 (Continued)
Allocation concealment (selection bias) Unclear risk Information not provided in the
manuscript
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding; both interventions were ex-
plained to participants at baseline: “The na-
ture of each of the two procedures was de-
scribed in detail, and the patients were as-
sured that there were no harmful side ef-
fects to be afraid of.” Information about
personnel blinding was not provided in the
manuscript
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Information not reported in the
manuscript
Incomplete outcome data (attrition bias)
All outcomes
High risk Data were omitted for 4 participants be-
cause of inadequate use (not specified) of
rating scales. Data for “specific and non-
specific effects” for 2 participants were in-
complete due to a lack of co-operation (not
explained). Handling of missing data was
not described
Selective reporting (reporting bias) Unclear risk Between-group differences at 6 weeks were
not reported
Other bias Low risk No prospective protocol available. No
other biases identified
Henry 2015
Methods 2-arm, single-centre, randomised, controlled (parallel) trial with 3 to 4 months duration
of treatment and 3 to 4 months duration of follow-up
Participants Setting: patients were screened and treated at the National Center for Rehabilitative
Auditory Research (NCRAR) located at the Portland (Oregon) Veterans Affairs Medical
Center, USA
Sample size:
• Number randomised: 30
• Number completed: 30
Participant (baseline) characteristics:
• Age: mean age was 67.9 years (SD 11) in the group receiving combination aids
and 66.5 years (SD 7.4) in the group receiving hearing aids
• Gender: the group who received combination aids included 5 women and 10
men, and the group receiving hearing aids included 3 women and 12 men
• Other characteristics:
Tinnitus duration varied between under 1 year and over 20 years. The group receiving
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Henry 2015 (Continued)
combination aids and hearing aids reported tinnitus duration of: < 1 year (3% and
0% respectively), 1 to 2 years (7% and 7%), 3 to 5 years (3% and 0%), 6 to 10 years
(10% and 13%), 11 to 20 years (27% and 27%), > 20 years (40% and 46%), and
10% and 7% were unsure of duration. Groups did not differ significantly on the above
characteristics. The mean Tinnitus Functional Index score at baseline was 60.5 (SD 15.
3) for the combination aid group and 56.1 (16.5) for the hearing aids group
Data for tinnitus laterality, baseline tinnitus loudness and quality, and baseline anxiety/
depression were not reported. However, to qualify for a hearing aid assessment, candidates
needed to have a symmetrical (defined as a difference between left and right ear 4-
frequency (0.5, 1, 2, 4 kHz) pure-tone averages of 15 dB or less) sensorineural hearing
loss within the mild to moderately severe range (4-frequency pure-tone average 25 to 70
dB HL)
Inclusion criteria: (1) at least 18 years of age; (2) English-speaking; (3) perceived hearing
difficulties; (4) no hearing aid experience within the previous 12 months; (5) no mental,
emotional or health conditions that would prevent participating in the study (6) Tinnitus
and Hearing Survey minimum score of 4 on section A; if the score was 4 to 6, then at
least one of the items required a score of at least 3; (7) TFI score greater than 25; (8) a
pass on the Mini Mental State Exam; (9) symmetrical (defined as a difference between
left and right ear 4-frequency (0.5, 1, 2, 4 kHz) pure-tone averages of 15 dB or less)
sensorineural hearing loss within the mild to moderately severe range (4-frequency pure-
tone average 25 to 70 dB HL)
Exclusion criteria: (1) active external ear disease or conductive component to hearing
loss (i.e. abnormal tympanometry and/or air-bone gaps exceeding 10 dB at 2 consecutive
frequencies); (2) diagnosis of retrocochlear pathology, Ménière’s disease, endolymphatic
hydrops, or perilymphatic fistula; (3) presence of medical contraindications to a hearing
aid fitting, including sudden onset hearing loss, fluctuating hearing sensitivity, ear pain
and vertigo
Interventions Intervention group: combination device (n = 15)
Comparator group: amplification only (hearing aids, n = 15)
All participants were fitted bilaterally with a commercially available receiver-in-the-canal
combination device. For the intervention group, the noise generators were activated
and adjusted according to the participants’ individual preferences to achieve “immediate
relief from tinnitus”. More specifically, the amplitude- and frequency-modulated noise
stimulus was fine-tuned across 16 channels to each individual user in the effort to optimise
relief from tinnitus. Duration of treatment was 3 to 4 months
Use of additional interventions: both groups received the same scripted tinnitus coun-
selling (education) immediately after fitting and adjustments of the devices that described
how sound can be used to make tinnitus less of a problem. The counselling followed pp.
31-64 in the flip-chart counselling book Progressive Tinnitus Management: Counselling
Guide (Henry 2010).
Outcomes Primary: tinnitus symptom severity (Tinnitus Functional Index, TFI)
Secondary: Hearing Handicap Inventory for Elderly, interview
Outcomes were measured at 3 to 4 months
Funding sources This research was funded by Starkey Hearing Technologies (387001) and by the De-
partment of Veterans Affairs, Rehabilitation Research & Development (RR&D) Service
(F7070-S and C9230-C)
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Declarations of interest Dr. Abrams is employed by Starkey Hearing Technologies, which funded the study.




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The authors stated that participants were
randomly allocated to groups but did not
provide any details on methods: “Partici-
pants were randomised to either the hear-
ing-aid-plus-noise (experimental) or the
hearing-aid-only (control) group.”
Allocation concealment (selection bias) Unclear risk Information not reported in the
manuscript
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were not blinded as 2 different
types of instruments were fitted, one being
a hearing aid and one combination hear-
ing aid. There is no evidence of blinding
of the personnel, outcome measures collec-
tion, counselling and interviews seemed to
be performed by the same people
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No evidence of blinding; audiologists
seemed to perform both instrument check-
ing and collecting outcome assessments.
Data were entered into the database by the
NCRAR data manager and analyses over-
seen by NCRAR biostatistician, however it
is stated that “data were analysed for the
two groups separately: experimental and
control” and blinding is not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Main outcome data complete. No loss to
follow-up.
Selective reporting (reporting bias) Low risk No prospective protocol available but all
listed outcomes reported in full
Other bias Low risk No prospective protocol available. No
other biases identified
41Sound therapy (using amplification devices and/or sound generators) for tinnitus (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Henry 2017
Methods 3-arm, single-centre, randomised, controlled (parallel) trial with 4 to 5 months duration
of treatment and 1 to 3 weeks, 2 months and 4 to 5 months (primary endpoint) duration
of follow-up
Participants Setting: patients were screened and treated at the National Center for Rehabilitative
Auditory Research (NCRAR) located at the VA Portland Health Care System (VA-
PORHCS), USA
Sample size:
• Number randomised: 55
• Number completed: 54
55 participants were enrolled, but 1 participant was lost at follow-up. Sample size was
based on an interim power analysis conducted after the first 21 participants had been
randomised. For a total of 55 participants, this analysis gave better than 87% power to
detect a significant contrast between the Extended Wear Hearing Aid and the conven-
tional hearing aid, and better than 80% power to detect a significant contrast between
the combination device and conventional hearing aid
Participant (baseline) characteristics:
• Age: the group who received combination aids had a mean age of 64 years (range
54 to 75 years). The group who received hearing aids had a mean age of 61.1 years
(range 48 to 75 years).
• Gender: the group who received combination aids included 4 women and 15
men. The group who received hearing aids included 4 women and 14 men.
• Other characteristics:
There were no significant between-group differences on any of the baseline measures.
The group who received combination aids had a baseline mean TFI score of 57.1, and
mean 4-frequency (0.5, 1, 2 and 4 kHz) pure-tone average of 35.5 (SD 8.7) and 34.
9 (SD 10; left and right ear respectively). The group who received hearing aids had a
baseline mean TFI score of 57.2, and mean 4-frequency (0.5, 1, 2 and 4 kHz) pure-tone
average of 36.9 (SD 8) and 34.9 (SD 9; left and right ear respectively). The group who
received extended wear hearing aids (EWHA) had a mean age of 64.3 years (range 33 to
81 years), included 4 women and 14 men, baseline mean TFI score of 54.1, and mean
4-frequency (0.5, 1, 2, and 4 kHz) pure-tone average of 39.2 (SD 6.4) and 39.6 (SD 6.
6; left and right ear respectively). Data for duration and laterality of tinnitus, baseline
tinnitus loudness and characteristics, baseline depression and anxiety were not provided
Inclusion criteria: participants were required to report both a suspected hearing loss
and bothersome tinnitus. More specifically, the 10-item Tinnitus and Hearing Survey
was administered over the phone, requiring a minimum total score of 4 on the tinnitus
section A. In addition, they needed to speak fluent English, not have worn hearing aids
for the past 6 months, and report being in good mental, emotional and health conditions
to comply with full study participation
Exclusion criteria: the EWHA had manufacturer-defined medical and lifestyle con-
traindications (e.g. radiation to head or neck, scuba diving, skydiving) that precluded
wearing the EWHA. If candidates could not be fit bilaterally with both types of hearing
aids, they were not eligible to participate
Interventions Intervention group 1: combination device (n = 19)
Intervention group 2: amplification only (conventional hearing aids, n = 19)
Intervention group 3: amplification only (extended wear hearing aids, n = 18)
The combination device group was fitted with Audeo Q line of receiver-in-the-canal
(RIC) hearing instruments with sound generator (Audeo Q90 312-T; Phonak). The
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hearing aids group was fitted AudeoQ line of RIC hearing instruments (Audeo Q90 312-
T; Phonak). The EWHA group was fitted with the extended-wear, deep seated device
(Lyric; Phonak). Duration of treatment was 4 to 5 months
Use of additional interventions: all 3 groups received informational counselling, which
took place following device fitting and adjustment. Hearing aid orientation and infor-
mational counselling involved use of a device-specific PowerPoint presentation to ensure
that standardised information was provided. Content included information about use,
care, troubleshooting and maintenance of the device; communication tips, both with
and without amplification; safety issues; goals and realistic expectations of amplification;
and overall adjustment to amplification. Hearing aid and combination aid participants
practised insertion and removal; learned how to adjust the volume, change the batteries
and distinguish right/left devices; and verified cell and/or landline phone compatibility.
EWHA participants learned how to adjust the volume, change the listening modes (on/
off/sleep) and remove the devices if necessary. They also watched a video demonstrating
these device-specific manipulations produced by the manufacturer
All participants received the same scripted counselling to describe briefly how sound
can be used to make tinnitus less problematic. The counselling followed pages 31-64
in a flip-chart counselling guide (Henry et al, 2010a). Participants also received a copy
of a tinnitus self-help workbook (Henry et al, 2010b) to read on their own (their use
of the workbook was not tracked). The research audiologists were available to answer
questions or address concerns at any time during study participation. Participants were
telephoned within 2 business days of the fitting appointment to ensure that the devices
were comfortable and working properly
Outcomes Primary: tinnitus symptom severity (Tinnitus Functional Index, TFI)
Secondary: Quick Speech in Noise, Hearing Handicap Inventory for the Elderly/Adults,
12-item version of the Speech, Spatial, and Qualities of Hearing questionnaire, Interna-
tional Outcome Inventory for Hearing Aids and a semi-structured exit interview devel-
oped specifically for this study
Outcomes were measured at 1 to 3 weeks, 2 months and 4 to 5 months
Funding sources Not reported
Declarations of interest Not reported
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Within ~4 weeks of the initial assessment,
eligible candidates returned to the labo-
ratory and were randomized into one of
three groups: (a) EWHA, (b) HA, or (c)
HA + SG. A simple randomization alloca-
tion method was sued. The random allo-
cation sequence was generated using com-
puter software.”
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Allocation concealment (selection bias) Low risk “Allocation concealment was achieved us-
ing sequentially numbered, opaque, sealed
envelopes, which were opened by study
staff to randomize and enrol participants.”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were not blinded as 3 different
types of instruments were fitted, one be-
ing a conventional hearing aid, one a com-
bination hearing aid and one an extended
wear hearing aid. There is no evidence of
blinding of the personnel: outcome mea-
sures collection, counselling and scripted
questions seemed to be performed by the
same person
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Information not provided in the
manuscript
Incomplete outcome data (attrition bias)
All outcomes
Low risk Main outcome data almost complete; only
1 participant (out of 55) lost to follow-up
in the EWHA group (did not provide any
follow-up data)
Selective reporting (reporting bias) Low risk No prospective protocol available but all
listed outcomes reported in full
Other bias Unclear risk No prospective protocol available. Fund-
ing and conflicts of interest were not re-
ported; all devices tested were manufac-
tured by Phonak, LLC: any links with the
company are not clear
Melin 1987
Methods 2-arm, single-centre, randomised, controlled (parallel) trial with 6 weeks duration of
treatment and 6 weeks duration of follow-up
Participants Setting: patients were screened and treated at the hearing centre at a Swedish university
hospital
Sample size:
• Number randomised: 39
• Number completed: 39
Participant (baseline) characteristics:
• Age: the group who received hearing aids had a mean age of 73.1 years (SD 12;
range 50 to 87 years) and the waiting list control group had a mean age of 72.2 (SD 9.
5; range 53 to 87)
• Gender: the hearing aids group included 13 women and 7 men and the waiting
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list control included 13 women and 6 men
• Other characteristics:
Tinnitus duration was from ≤ year to over 5 years in both groups. Participants reported
their tinnitus to be in both ears (n = 12 in both groups), one ear (n = 6 in hearing
aids group and n = 3 in waiting list control), both ears and head (n = 2 and n =
3, respectively), 1 participant in hearing aid group reported tinnitus in the head and
1 in waiting list control reported tinnitus in left ear and the head. The severity of
tinnitus was classified into 3 grades. 7 participants in the hearing aid group and 10
in the waiting list group were classified as tinnitus severity Grade 1 (audible only in
quiet environment), 11 and 9 respectively as Grade 2 (audible in ordinary but not in
noisy environments; not noticeable in specific situations, such as when the attention is
focused on interesting work etc.; occasionally causes disturbances in sleep), and 2 and 0
respectively as Grade 3 (constantly noticed in all ordinary acoustical environments and
causing severe disturbances of concentration and continuous disturbance of sleep). Mean
pure tone average (0.5, 1 and 2 kHz) was 39.4 (SD 10.9) in right and 40.4 (SD 12.7) in
left ear for hearing aid group and 38.7 (SD 15.8) in right and 42 (SD 11.4) in left ear
for waiting list controls. No statistical analyses of differences between groups regarding
baseline characteristics were reported. From 39 participants taking part in the study 87%
had bilateral hearing loss and 56% claimed that hearing was their main problem
Inclusion criteria: hearing impairment to such a degree that hearing aids are needed,
no earlier experience of hearing aids, tinnitus of more than 6 months duration
Exclusion criteria: not reported
Interventions Intervention group: amplification only (hearing aids, n = 20)
Comparator group: waiting list (n = 19)
18 participants in the hearing aid group were fitted unilaterally and 2 bilaterally. Hearing
aids fittings were conducted according to a standard procedure and comprised of 4 visits
- for information, fitting, practice and adjustment of the aid
Use of additional interventions: participants fitted with hearing aids received informa-
tion (not specified)
Outcomes Hearing ability in 4 different hearing situations was assessed using a visual analogue
scale (VAS) (from “no hearing at all” to “complete hearing ability”). Tinnitus in 4
different hearing situations was assessed using a VAS (from “no tinnitus” to “worst
tinnitus ever”). Semi-structured interviews with force-choice answers asked whether the
hearing impairment or tinnitus was the main problem, about fluctuations in annoyance
caused by tinnitus and problems such as muscle tension, headaches and dizziness, general
expectations of the hearing aid and its potential ability to decrease tinnitus, frequency and
duration of hearing aid use, whether the use of hearing aid had influenced the tinnitus
in any way
Funding sources This study was supported financially by the Bank of Sweden Tercentenary Foundation
(Grant No. 83/16) and grants from Stiftelsen Tysta Skolan, Stockholm and the Oticon
Foundation, Copenhagen
Declarations of interest Not reported
Notes -
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Melin 1987 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Manuscript reports use of a randomisation
plan but provides no details: “During the
first 6 weeks of the study, the experiment
had a between-group design, where sub-
jects were randomly assigned to one of two
groups. Group 1 was fitted with hearing
aids, while group 2 served as a waiting list
control group. To prevent bias, the random
allocations of the subjects were done after
their first interview according to randomi-
sation plan.”
Allocation concealment (selection bias) Unclear risk Information not reported in the
manuscript
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were not blinded as they were
either fitted with hearing aids or served
as a waiting list control. Personnel were
not blinded - assessments (visual analogue
scales and interviews) were performed by 3
audiological assistants and the participants
always met the same assistant throughout
the rehabilitation programme
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Assessments were conducted by audiolog-
ical assistants but it is unlikely that they
were blinded as one group was fitted with
hearing aids and the other was a waiting list
control, and assistants were conducting in-
terviews. It was not stated who conducted
the analysis
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcomes reported in detail
Selective reporting (reporting bias) Unclear risk No dropout reported for experimental pe-
riod. Unclear if all interview question data
are reported
Other bias Low risk No prospective protocol available. No
other potential biases identified
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Parazzini 2011
Methods 2-arm, 2-centre, randomised, controlled (parallel) trial with 12 months duration of
treatment and 3 (primary endpoint), 6 and 12 months duration of follow-up
Participants Setting: patients were screened and treated in 1 of 2 tinnitus clinics (Italy or USA)
Sample size:
• Number randomised: 101
• Number completed: 91
101 patients were enrolled, but due to missing records the final data set included only
91 patients
Participant (baseline) characteristics:
• Age: group level data for age were not provided. The 91 patients included in the
final analysis had a mean age of 38.8 years (SD 18.1).
• Gender: the group who received hearing aids included 21 women and 28 men,
and the group receiving sound generators included 19 and 23 men
• Other characteristics:
The 91 patients included in the final analysis had a mean tinnitus duration of 69.5
months (SD 89.7). Baseline measures included an audiological test for hearing loss. Mean
hearing loss was not reported per group but inclusion in the study required patients
to have hearing levels < 25 dB at 2 kHz and > 25 dB at frequencies higher than 2
kHz. This was taken as the borderline between two categories: “no hearing loss” and
“significant hearing loss”. According to Jastreboff 2004, patients with this hearing level
can be managed with either hearing aids or sound generators. The participants in this
study therefore had a very particular audiological profile. Patients who had previously
been prescribed hearing aids were excluded from participation in the trial
The mean Tinnitus Handicap Inventory (THI) score at baseline was 57 for the hearing
aid group and 59 for the sound generator group
Inclusion criteria: (1) borderline between category 1 and category 2 (according to
Jastreboff classification, TRT); (2) HL ≤ 25 dB at 2 kHz and HL ≥ 25 dB at frequencies
higher than 2 kHz; (3) all tinnitus aetiologies excluding Ménière’s and middle-external
ear disease; (4) tinnitus duration of at least 6 months; (5) bilateral symmetrical hearing
loss (i.e. difference less than 15 dB); (6) age between 18 and 75 years
Exclusion criteria: Ménière’s and middle-external ear disease, tinnitus retraining therapy
in the past, hearing aids in the past
Interventions Intervention group 1: tinnitus retraining therapy with amplification only (hearing aids,
n = 49)
Intervention group 2: tinnitus retraining therapy with sound generators (n = 42
All hearing aid patients were fitted with the ’ResoundAir’ device (GN Resound), pro-
grammed according to standard audiological practice. In terms of the type of sound
generators, all patients were fitted with behind-the-ear open fit ’Silent Star’ devices (Vi-
ennatone) which produce a broadband sound. All patients received the same educational
counselling component of tinnitus retraining therapy (TRT), with follow-up to optimise
the therapy at 3, 6 and 12 months
Use of additional interventions: none
Outcomes Primary: tinnitus symptom severity (Tinnitus Handicap Inventory, THI)
Secondary: a number of visual analogue scales were used to rate tinnitus loudness over
the preceding month (rated from 0 = no tinnitus to 10 = “as loud as you can imagine”)
, effect on life, tinnitus annoyance, percentage of time when patients were annoyed and
percentage of time when patients were aware of their tinnitus
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Parazzini 2011 (Continued)
Outcomes were measured at 3, 6 and 12 months during the tinnitus treatment
Funding sources This research was partially supported by grants from the Tinnitus Research Initiative,
by Fondazione Ascolta e Vivi, and GN ReSound A/S
Declarations of interest The authors reported no conflict of interest
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Specifically, subjects were randomly as-
signed to two treatments groups: half of
the subjects were fitted with binaural sound
generators (identified in the subsequent
text as the SG group), whereas the other
half were fitted with binaural open ear hear-
ing aids (identified in the subsequent text
as the OE-HA group). Randomization was
obtained on the basis of a random table.”
Allocation concealment (selection bias) Unclear risk Information not reported in the
manuscript
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were not blinded; 2 different
types of devices were fitted: hearing aids or
sound generators. Counselling was likely
tailored to the device option that partici-
pants received (according to TRT). There
is no statement about the blinding of the
personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Information not reported in the
manuscript
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 10 participants out of 101 excluded due to
missing recordings (not explained). Struc-
tured interview data were recorded, anal-
ysed and reported for the subset of 51 out
of 91 participants only
Selective reporting (reporting bias) Low risk All listed outcomes reported
Other bias Low risk No prospective protocol available. No
other potential biases identified
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Stephens 1985
Methods 3-arm, single-centre, randomised, controlled (parallel) trial with 6 months duration of
treatment and 6 months duration of follow-up; sub-study as a part of a multi-centre
study of tinnitus maskers (Stephens 1985, Hazell 1985 paper)
Participants Setting: patients were screened and treated at the Royal National Throat, Nose and Ear
(RNTNE) Hospital, UK
Sample size:
• Number randomised: 147
• Number completed: 147
147 participants (out of 285; Hazell 1985) took part in the randomised part of the study.
Of those 75 reported no hearing disability and 72 complained of hearing disability
Participant (baseline) characteristics:
• Age: age distribution in all participants was: (i) < 20 years (n = 2); (ii) 20 to 29
years (n = 5); (iii) 30 to 39 years (n = 18); (iv) 40 to 49 years (n = 25); (v) 50 to 59
years (n = 54); (vi) 60 to 69 years (n = 39); and (vii) 70 to 79 years (n = 10)
• Gender: the 153 patients included in the study included 77 men and 76 women
• Other characteristics:
Group level data for any of the baseline characteristics were not provided by Stephens
1985. Tinnitus duration was: 3 to 6 months (3.3%), 6 to 12 months (21.5%), 1 to 5
years (47%) and > 5 years (28.2%). Patients reported tinnitus localised in right ear only
(21.5%), left ear only (23.5%), equal in both ears (16.8%), in both ears, most in left (19.
5%), in both ears most in right (10.7%), and in the head (8.1%). 34% of participants
reported hearing one sound and 67% more than one sound. Hearing threshold at 1 kHz
was ≤ 20 dB in 84 participants, 20 to 45 dB in 34 participants, 50 to 70 dB in 18
participants, and over 70 dB in 10 participants
Inclusion criteria: (1) tinnitus as a main complaint, with or without hearing loss; (2)
tinnitus as a major problem (Hazell 1985); (3) tinnitus duration minimum 3 months;
(4) English language knowledge enough to fill in the questionnaire; (5) no restrictions
on hearing level; (6) no new treatment during the trial period; (7) no severe inter-current
illness during trial; (8) no intensive psychiatric treatment
Exclusion criteria: tinnitus as secondary complaint, inability to complete questionnaire,
tinnitus duration less than 3 months, being unwell, major psychological treatment,
refusing allocation, missing data (Stephens 1985, Hazell 1985 paper)
Interventions Participants who reported no hearing disability:
Intervention group 1: A&M sound generator (n = 24)
Intervention group 2: Viennatone sound generator (n = 27)
Comparator group: limited counselling (no instrument fitting, n = 24)
Participants who reported hearing disability:
Intervention group 1: amplification only (hearing aid, n = 26)
Intervention group 2: combination device (n = 23)
Intervention group 3: A&M sound generator (n = 23)
Sound generators and combination devices were fitted unilaterally but hearing aids were
fitted unilaterally or bilaterally, according to normal clinical indications. Hearing aids
were standard National Health Service behind-the- ear devices. Combination aids fit-
ted were Danavox 775-PP-AGC/masker module combination instruments. Duration
of treatment was 6 months. All participants had a month review to ensure adequate
management of their devices and counselling advice, repairs, modification of frequency
responses, ear-mould changes (if necessary repeated with 1-month intervals)
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Stephens 1985 (Continued)
Use of additional interventions: those fitted with instruments all received a similar
counselling in addition to the fitting of appropriate instrumentation
Outcomes Effectiveness of the interventions was measured using the Masker Effectiveness Ques-
tionnaire, changes in the Crown Crisp Experiential Index, changes in the Semantic Dif-
ferential scores, and for a subset of patients the long pattern of instrument use and needs
for other therapy. Stephens 1985 measured anxiety, phobic anxiety, somatic anxiety and
depression subscales of the Crown Crisp Experiential Index (data for the randomised
and non-randomised group together available in Stephens 1985, Hazell 1985 paper),
however data for the randomised part of the study were not reported in the manuscript.
Health-related quality of life as measured by a validated instrument was not measured
in the included studies
Outcomes were measured at 6 months
Funding sources The maskers and combination instruments used in this study, together with some of
the test equipment, were provided by a grant from the UK Department for Health and
Social Security as part of the larger study on tinnitus maskers
Declarations of interest Not reported
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Manuscript reports use of a randomisation
plan but provides no details: “At this time,
the patients were allocated to treatment
groups. Thus, those reporting no hearing
disability were randomly allocated to either
a control group with limited counselling
but no instrument fitting, to fitting with
an A&M masker or to fitting with Vienna-
tone masker. Those complaining of hear-
ing disability were similarly randomly allo-
cated to a hearing aid fitting with a stan-
dard National Health Service behind the
ear aid(s), fitting with Danavox 775-PP-
AGC/masker module combination instru-
ment, or fitting with and A&M tinnitus
masker.”
Allocation concealment (selection bias) Unclear risk No allocation concealment described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were not blinded as they were
fitted with different types of instruments
(hearing aid, combination aid, masker) or
were in the no device group. Personnel were
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Stephens 1985 (Continued)
not blinded; the same therapist was see-
ing the participant throughout the study
and collected outcome measures. Differ-
ences between therapists regarding the re-
sults were reported
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded; differences between therapists
were reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Stephens 1985, Hazell 1985 paper, reports
153 patients starting the study and 119
reaching the first evaluation. However, data
from only 147 participants are reported in
Stephens 1985. Dropouts not explained
Selective reporting (reporting bias) Low risk All listed outcomes reported
Other bias High risk Differences between therapists reported.
Only some of the patients underwent full
neuro-otological examination. No prospec-
tive protocol available. No other potential
biases identified
Zhang 2013
Methods 2-arm, single-centre, randomised, controlled (parallel) trial with 12 months duration of
treatment and 12 months duration of follow-up
Participants Setting: patients were screened and tested at the Tianjin Medical University General
Hospital Outpatient Clinic, China
Sample size:
• Number randomised: 154
• Number completed: 154
Participant (baseline) characteristics:
• Age: 154 participants who took part in the study had a mean age of 65.6 years
(age range 50 to 79 years).
• Gender: 154 participants who took part in the study included 71 women and 83
men
• Other characteristics:
Group level data for the baseline characteristics were not reported. 154 participants who
took part in the study had a mean duration of tinnitus of 8.8 years (range 1 to 28 years)
. 33 participants reported their tinnitus to be low-key buzz and 121 reported high-key
cicadas. Mean duration of hearing disorder was 10.5 years (SD 7.3; range 1 to 35 years).
Report stated that there was no clear difference between the compared groups in baseline
measures. Hearing loss degree was not reported, however the inclusion criterion for the
study was moderate to severe hearing loss (speech frequency threshold verge from 41 to
90 dB through pure tone test, according to the WHO, ISO (1980) hearing loss grading
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Zhang 2013 (Continued)
standard). Baseline tinnitus severity was not reported, however the inclusion criterion
stated long-term, severe tinnitus, affecting work and life (such as affecting sleep and
work, anxiety, depression etc.). Baseline tinnitus loudness, laterality and baseline anxiety/
depression was not reported
Inclusion criteria: (1) patients with tinnitus that is affecting work and life, such as
affecting sleep and work, causes anxiety or depression, etc; (2) patients with moderate
to severe hearing loss (speech frequency threshold verge from 41 to 90 dB through pure
tone test, according to the WHO, ISO (1980) hearing loss grading standard); (3) age >
50 years
Exclusion criteria: (1) objective tinnitus (such as pulsating tinnitus); (2) patients with
acute middle ear discharge or sudden deafness within 3 months before enrolment; (3)
patients with severe internal medical conditions, such as not well controlled hyperten-
sion, diabetes and cardiovascular disease; (4) patients with definite organic diseases that
cause tinnitus, such as diseases of external or middle ear, noise-induced hearing damage,
Ménière’s disease, acoustic neuroma, etc; (5) patients with severe mental illness or mental
disorder; (6) patients with hyperacusis or poor comprehension and expression; or (7)
patients who cannot perform routine hearing tests
Interventions Intervention group: amplification only and relaxation (hearing aid, n = 84)
Comparator group: relaxation only (n = 70)
Hearing aids fitted were manufactured by GN ReSound, Denmark. Both groups prac-
tised relaxation twice daily for 10 to 20 minutes, usually in the morning and before
sleeping. Duration of the intervention was 12 months
Use of additional interventions: both groups had undergone some “counselling” that
included: (i) diagnosis of patient’s tinnitus symptoms, explaining relevant knowledge,
pathophysiological aspects and prognosis about tinnitus; (ii) learning how to adapt to
the tinnitus condition (e.g. the patient could compare tinnitus to a roar of a train, the
noise of a refrigerator, or snoring); (iii) attention distraction (turning attention to other
interesting things, e.g. reading newspaper, watching TV or listening radio); (iv) relaxation
training
Outcomes Tinnitus symptom severity, was assessed by criteria for therapeutic effect as follows: (i)
complete adaptation: tinnitus symptom disappears or significantly relieves, with normal
emotion, sleeping, work and life; (ii) basic adaptation: tinnitus symptom disappears,
relieves or still exists, but with normal emotion, sleeping, work and life; (iii) partial
adaptation: tinnitus still exists, partial affecting emotion, sleeping, work and life; (iv)
no adaptation: tinnitus symptom still exists or even worse, seriously affecting emotion,
sleeping, work and life
The patients had outpatient visits at baseline, 3, 6 and 12 months
Funding sources Hearing aids were provided by Disabled Persons’ Federation
Declarations of interest Not reported
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Zhang 2013 (Continued)
Random sequence generation (selection
bias)
Unclear risk The authors stated that participants were
randomly allocated to groups but did not
provide any details on the method
Allocation concealment (selection bias) Unclear risk Information not reported in the
manuscript
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were not blinded; hearing aids
were used in only one group and the other
group received only counselling
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Information not reported in the
manuscript
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing outcome data
Selective reporting (reporting bias) Low risk All outcomes stated in the methods were
reported in the results
Other bias Low risk No prospective protocol available. No
other potential biases identified
EWHA: extended wear hearing aids
HL: hearing level
SD: standard deviation
TFI: Tinnitus Functional Index
THI: Tinnitus Handicap Inventory
TRT: tinnitus retraining therapy
VAS: visual analogue scale
WHO: World Health Organization
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Al-Jassim 1988 ALLOCATION: not randomised; preference study
Andersson 2002 ALLOCATION: not randomised; the study used a 2 x 3 mixed experimental design
Benton 2016 ALLOCATION: not randomised; survey study
Del Bo 2006 ALLOCATION: not randomised; before-and-after study; all participants were fitted with hearing aids
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Durai 2017 ALLOCATION: randomised cross-over trial
PARTICIPANTS: adults with tinnitus
INTERVENTION: equivalence study comparing 2 different sound conditions (broadband noise versus
natural sounds via MP3 player), no control condition included
Gudex 2009 ALLOCATION: not randomised; cohort study
Henry 2016 ALLOCATION: randomised controlled trial
PARTICIPANTS: adults with tinnitus
INTERVENTION: main goal of the study was to compare tinnitus masking (TM) with tinnitus retraining
therapy (TRT). Those were also compared to a tinnitus education (TE) group (where only some patients
were fitted with hearing aids) and a waiting list control. Within the TM and TRT groups participants were
fitted with a mix of devices: hearing aids, combination aids or sound generators. Within the TE group
only some participants were fitted with hearing aids
Hernández Moñiz 1998 ALLOCATION: not randomised; cohort study
Hiller 2005 ALLOCATION: not randomised; although the initial allocation of participants was randomised, partici-
pants were moved between the study arms after randomisation
Hodgson 2017 ALLOCATION: randomised cross-over trial
PARTICIPANTS: adults with tinnitus
INTERVENTION: equivalence study comparing hearing aids with wide dynamic range compression
with hearing aids with frequency compression; no control condition included
Lipman 2007 ALLOCATION: not randomised; all participants started with 2 weeks of control condition followed by
2 weeks of active treatment
Mehlum 1984 ALLOCATION: randomised but not controlled trial. Participants tested 4 different devices in random
order but no planned comparisons after each device were included
Shabana 2018 ALLOCATION: not randomised; participants were “divided into two equal well-matched groups”
Strauss 2015 ALLOCATION: randomised controlled trial
PARTICIPANTS: adults with tinnitus
INTERVENTION: equivalence study, comparing a hearing aid with standard amplification to the same
hearing aid with notched amplification; no control condition included
Sweetow 2010 ALLOCATION: not randomised; uncontrolled before-and-after study
Tao 2017 ALLOCATION: randomised controlled trial
PARTICIPANTS: adults with tinnitus
INTERVENTION: equivalence study comparing 2 types of masking therapy (multiple-frequency
matched masking versus single-frequency masking); no control condition included
Thedoroff 2017 ALLOCATION: randomised controlled trial
PARTICIPANTS: adults with tinnitus
INTERVENTION: equivalence study (3 types of sound therapy devices that differed in the acoustic
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stimulus used); no control condition included
Characteristics of ongoing studies [ordered by study ID]
ISRCTN15178771
Trial name or title Efficacy of a combination hearing aid and sound generator
Methods 2-arm, randomised, controlled (parallel) trial
Participants Adults with tinnitus and hearing loss, GAD-7 anxiety screening: score from 0 to 9, indicating no anxiety or
minimal to mild anxiety only, PHQ-9 depression screening: score from 0 to 9, indicating no depression or
minimal to mild depression only, TFI questionnaire: tinnitus symptoms ranging in severity rating from ≥ 32
to ≤ 71 points
Interventions Intervention group 1: combination device
Intervention group 2: amplification only (hearing aid)
Outcomes Tinnitus Functional Index (TFI) to measure tinnitus severity, Tinnitus Acceptance Questionnaire (TAQ),
My Tinnitus document (self-report of symptoms), Hearing Handicap Inventory (HHIA/HHIE) self-report
measure of hearing-related disability, patient interviews at each visit
Starting date 1 April 2015
Contact information Dr David Baguley, National Institute for Health Research Nottingham Hearing Biomedical Research Centre,
Ropewalk House, 113 The Ropewalk, Nottingham, NG1 5DU
Notes ISRCTN Registry identifier: ISRCTN15178771. Contacted - trial ongoing
TCTR20180225002
Trial name or title A randomized controlled trial of music therapy in tinnitus patient
Methods 3-arm, double-blind, randomised, controlled (parallel) trial
Participants Adults aged 18 to 60 years with tinnitus, Tinnitus Handicap Inventory score equal or more than 38, General
Health Questionnaire Score less than 6
Interventions Intervention: Notch-Music (experimental)
Active comparator: conventional music
Control: counselling (counselling patients to ignore the tinnitus and find other activity to distract themselves
from tinnitus)
Outcomes Tinnitus Handicap Inventory, Pittsburgh Sleep Quality Index
Starting date 23 February 2018
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TCTR20180225002 (Continued)
Contact information Chompunut Srisukhumchai, Khon Kaen University, Phone: +66 845105131, Email:
csrisukhumchai@gmail.com, Postal Address: 916 Moo.12 Sila Muang Khon Kaen Thailand, State/Province:
Khon Kaen, Postal Code: 40000, Country: Thailand
Notes Thai Clinical Trials Registry identifier: TCTR20180225002
GAD-7: Generalised Anxiety Disorder assessment
PHQ-9: Patient Health Questionnaire-9
TFI: Tinnitus Functional Index
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D A T A A N D A N A L Y S E S
Comparison 1. Hearing aid only compared to sound generator only for tinnitus




participants Statistical method Effect size
1 Tinnitus symptom severity at 3
months
1 91 Mean Difference (IV, Fixed, 95% CI) 1.30 [-5.72, 8.32]
2 Tinnitus symptom severity at 6
months
1 91 Mean Difference (IV, Fixed, 95% CI) -1.80 [-8.82, 5.22]
3 Tinnitus symptom severity at 12
months
1 91 Mean Difference (IV, Fixed, 95% CI) -0.90 [-7.92, 6.12]
Comparison 2. Combination hearing aids compared to hearing aids for tinnitus




participants Statistical method Effect size
1 Tinnitus symptom severity at 3
to 5 months
3 114 Std. Mean Difference (IV, Fixed, 95% CI) -0.15 [-0.52, 0.22]
Analysis 1.1. Comparison 1 Hearing aid only compared to sound generator only for tinnitus, Outcome 1
Tinnitus symptom severity at 3 months.
Review: Sound therapy (using amplification devices and/or sound generators) for tinnitus
Comparison: 1 Hearing aid only compared to sound generator only for tinnitus
Outcome: 1 Tinnitus symptom severity at 3 months





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Parazzini 2011 49 -18.9 (18.36) 42 -20.2 (15.8) 100.0 % 1.30 [ -5.72, 8.32 ]
Total (95% CI) 49 42 100.0 % 1.30 [ -5.72, 8.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Hearing aid Sound generator
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Analysis 1.2. Comparison 1 Hearing aid only compared to sound generator only for tinnitus, Outcome 2
Tinnitus symptom severity at 6 months.
Review: Sound therapy (using amplification devices and/or sound generators) for tinnitus
Comparison: 1 Hearing aid only compared to sound generator only for tinnitus
Outcome: 2 Tinnitus symptom severity at 6 months





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Parazzini 2011 49 -25.6 (18.36) 42 -23.8 (15.8) 100.0 % -1.80 [ -8.82, 5.22 ]
Total (95% CI) 49 42 100.0 % -1.80 [ -8.82, 5.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Hearing aid Sound generator
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Analysis 1.3. Comparison 1 Hearing aid only compared to sound generator only for tinnitus, Outcome 3
Tinnitus symptom severity at 12 months.
Review: Sound therapy (using amplification devices and/or sound generators) for tinnitus
Comparison: 1 Hearing aid only compared to sound generator only for tinnitus
Outcome: 3 Tinnitus symptom severity at 12 months





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Parazzini 2011 49 -30.1 (18.36) 42 -29.2 (15.8) 100.0 % -0.90 [ -7.92, 6.12 ]
Total (95% CI) 49 42 100.0 % -0.90 [ -7.92, 6.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Hearing aid Sound generator
Analysis 2.1. Comparison 2 Combination hearing aids compared to hearing aids for tinnitus, Outcome 1
Tinnitus symptom severity at 3 to 5 months.
Review: Sound therapy (using amplification devices and/or sound generators) for tinnitus
Comparison: 2 Combination hearing aids compared to hearing aids for tinnitus
Outcome: 1 Tinnitus symptom severity at 3 to 5 months
Study or subgroup
Combination







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
dos Santos 2014 24 -28.25 (18.59) 23 -33.7 (24.18) 41.7 % 0.25 [ -0.33, 0.82 ]
Henry 2015 15 -39.3 (26.2) 15 -32.9 (14.03) 26.5 % -0.30 [ -1.02, 0.42 ]
Henry 2017 19 -33 (26.2) 18 -20.9 (14.03) 31.7 % -0.56 [ -1.22, 0.10 ]
Total (95% CI) 58 56 100.0 % -0.15 [ -0.52, 0.22 ]
Heterogeneity: Chi2 = 3.50, df = 2 (P = 0.17); I2 =43%
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Combination hearing aid Hearing aid
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A D D I T I O N A L T A B L E S
Table 1. Examples of questionnaires measuring tinnitus symptom severity
Measurement instrument (author, year) Number of items and subscales Internal consistency (Cronbach’s alpha for global
score)
Tinnitus Functional Index (Meikle 2012) 25 items, 8 subscales a = 0.97
Tinnitus Handicap Inventory (Newman
1996)
25 items, 3 subscales a = 0.93
Tinnitus Handicap Questionnaire (Kuk
1990)
27 items, 3 subscales a = 0.94
Tinnitus Questionnaire (Hallam 1996) 52 items, 5 subscales a = 0.94
Tinnitus Reaction Questionnaire (Wilson
1991)
26 items, 4 subscales a = 0.96
Tinnitus Severity Scale (Sweetow 1990) 15 items Not reported
A P P E N D I C E S
Appendix 1. Search strategies
CENTRAL (CRS) MEDLINE (Ovid) Embase (Ovid)
1 MESH DESCRIPTOR Tinnitus EX-
PLODE ALL AND CENTRAL:TARGET
2 (tinnit*):AB,EH,KW,KY,MC,MH,TI,
TO AND CENTRAL:TARGET 1
3 #1 OR #2 AND CENTRAL:TARGET
4 MESH DESCRIPTOR Hearing Aids
EXPLODE ALL AND CENTRAL:TAR-
GET
5 MESH DESCRIP-




3. 1 or 2
4. exp Hearing Aids/
5. exp Perceptual Masking/
6. exp Acoustic Stimulation/
7. Combined Modality Therapy/
8. exp Music Therapy/
9. SOUND/th, tu [Therapy, Therapeutic
Use]
10. (((hearing or tinnitus) adj3 aid?) or ear-
1. exp tinnitus/
2. tinnit*.ab,ti.
3. 1 or 2
4. exp hearing aid/
5. exp auditory stimulation/
6. exp music therapy/
7. exp auditory masking/
8. (((hearing or tinnitus) adj3 aid?) or ear-
mold? or (ear adj3 mold?)).ab,ti
9. (mask* or amplification).ab,ti.
10. (“therapeutic sound?” or “therapeutic
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6 MESH DESCRIPTOR Acoustic Stimu-
lation EXPLODE ALL AND CENTRAL:
TARGET
7 MESH DESCRIPTOR Combined
Modality Therapy AND CENTRAL:
TARGET
8 MESH DESCRIPTOR Music Therapy
EXPLODE ALL AND CENTRAL:TAR-
GET
9 MESH DESCRIPTOR Sound WITH
QUALIFIER TU,TH AND CENTRAL:
TARGET
10 (((hearing or tinnitus) NEAR (aid or
aids)) or earmold* or (ear NEAR mold*)
):AB,EH,KW,KY,MC,MH,TI,TO AND
CENTRAL:TARGET 657
11 (mask* or amplification):AB,EH,KW,
KY,MC,MH,TI,TO AND CENTRAL:
TARGET
12 (“therapeutic sound*” or “therapeu-
tic noise*” or “white noise*” or “tinni-
tus instrument*” or “combination instru-
ment*” or “combination device*” or “static
noise*” or “tinnitus device*” or “relief
product*” or “puretone device*” or “pure-
tone tinnitus” or “tinnitus system*”):AB,
EH,KW,KY,MC,MH,TI,TO AND CEN-
TRAL:TARGET
13 (tinnitech* OR starkey* OR ultraquiet*
or LTWN or MML or TCI or TRD or
hisonic* or oticon or phonak or ReSound
or widex or siemens or audeo or alta or
zen or danalogic or audimed or ipod):AB,
EH,KW,KY,MC,MH,TI,TO AND CEN-
TRAL:TARGET
14 ((auditory or audio or acoustic or
noise* or sound* or music or audio) NEAR
(stimulat* or generator? or device? or fre-
quency or stimulus)):AB,EH,KW,KY,MC,
MH,TI,TO AND CENTRAL:TARGET
15 ((noise* or sound* or music) near




16 (tinnitus near pitch* near match*):AB,
EH,KW,KY,MC,MH,TI,TO AND CEN-
TRAL:TARGET
17 #4 OR #5 OR #6 OR #7 OR #8 OR #
mold? or (ear adj3 mold?)).ab,ti
11. (mask* or amplification).ab,ti.
12. (“therapeutic sound?” or “therapeutic
noise?” or “white noise?” or “tinnitus in-
strument?” or “combination instrument?”
or “combination device?” or “static noise?”
or “tinnitus device?” or “relief product?” or
“puretone device?” or “puretone tinnitus”
or “tinnitus system?”).ab,ti
13. (tinnitech* or starkey* or ultraquiet*
or LTWN or MML or TCI or TRD or
hisonic* or oticon or phonak or ReSound
or widex or siemens or audeo or alta or zen
or danalogic or audimed or ipod).ab,ti
14. ((auditory or audio or acoustic or noise?
or sound? or music or audio) adj3 (stimu-
lat* or generator? or device? or frequency
or stimulus)).ab,ti
15. ((noise? or sound? or music) adj3
(therap*or training or treatment? or fre-
quency or intervention?)).ab,ti
16 (tinnitus adj3 pitch* adj3 match*).ab,ti.
17. or/4-16
18. 3 and 17
19. randomized controlled trial.pt.







27. 18 or 19 or 20 or 21 or 22 or 23 or 24
or 25
28. exp animals/ not humans.sh.
29. 27 not 28
30. 18 and 98 491
noise?” or “white noise?” or “tinnitus in-
strument?” or “combination instrument?”
or “combination device?” or “static noise?”
or “tinnitus device?” or “relief product?” or
“puretone device?” or “puretone tinnitus”
or “tinnitus system?”).ab,ti
11. (tinnitech* or starkey* or ultraquiet*
or LTWN or MML or TCI or TRD or
hisonic* or oticon or phonak or ReSound
or widex or siemens or audeo or alta or zen
or danalogic or audimed or ipod).ab,ti
12. ((auditory or audio or acoustic or noise?
or sound? or music or audio) adj3 (stimu-
lat* or generator? or device? or frequency
or stimulus)).ab,ti
13. ((noise? or sound? or music) adj3
(therap*or training or treatment? or fre-
quency or intervention?)).ab,ti
14. (tinnitus adj3 pitch* adj3 match*).ab,
ti.
15. or/4-14
16. 3 and 15
17. (random* or factorial* or placebo* or
assign* or allocat* or crossover*).tw
18. (control* adj group*).tw.
19. (trial* and (control* or comparative)).
tw.
20. ((blind* or mask*) and (single or double
or triple or treble)).tw
21. (treatment adj arm*).tw.
22. (control* adj group*).tw.
23. (phase adj (III or three)).tw.
24. (versus or vs).tw.
25. rct.tw.
26. crossover procedure/
27. double blind procedure/
28. single blind procedure/
29. randomization/
30. placebo/
31. exp clinical trial/
32. parallel design/
33. Latin square design/
34. 17 or 18 or 19 or 20 or 21 or 22 or 23
or 24 or 25 or 26 or 27 or 28 or 29 or 30
or 31 or 32 or 33
35. exp ANIMAL/ or exp NONHUMAN/
or exp ANIMAL EXPERIMENT/ or exp
ANIMAL MODEL/
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9 OR #10 OR #11 OR #12 OR #13 OR
#14 OR #15 OR #16 AND CENTRAL:
TARGET
18 #17 AND #3 AND CENTRAL:TAR-
GET 408
36. exp human/
37. 35 not 36
38. 34 not 37
39. 16 and 38 512
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We planned to perform a network meta-analysis, however this was not possible due to limited data from four included studies.
We have included two ’Summary of findings’ tables for additional comparisons for which we had data available (i.e. hearing aids versus
sound generators and combination devices versus hearing aids).
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